

66/71/70

A



Customer No. 20350

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
(415) 576-0200

Old 'S' N 1990 Priority Docket No. 17473-001110

**ASSISTANT COMMISSIONER FOR PATENTS
BOX PATENT APPLICATION
Washington, D.C. 20231**

"Express Mail" Label No. EM541290252US

Date of Deposit: April 14, 1999

I hereby certify that this is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" service
under 37 CFR 1.10 on the date indicated above, addressed to:

Sir:

Transmitted herewith for filing under 37 CFR 1.53(b) is the

- ☐ patent application of
☐ continuation patent application of
☐ divisional patent application of
☒ continuation-in-part patent application of

Assistant Commissioner for Patents
Washington, D.C. 20231

By: 

Inventor(s)/Applicant Identifier: Glenna C. Burner and Joseph P. Brown

For: NUCLEIC ACID SEQUENCES AND PROTEINS ASSOCIATED WITH AGING

☒ This application claims priority from each of the following Application Nos./filing dates:

60/081,887, filed April 15, 1998

the disclosure(s) of which is (are) incorporated by reference.

☐ Please amend this application by adding the following before the first sentence: "This application is a ☐ continuation ☐ continuation-in-part of and claims the benefit of U.S. Provisional Application No. 60/_____, filed _____, the disclosure of which is incorporated by reference."

Enclosed are:

- ☒ 70 page(s) of specification
☒ 11 page(s) of claims
☒ 1 page(s) of Abstract
☐ _____ sheet(s) of ☐ formal ☐ informal drawing(s).

An assignment of the invention to _____

☒ A ☐ signed ☒ unsigned Declaration & Power of Attorney

☒ A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 ☐ is enclosed ☐ was filed in the
prior application and small entity status is still proper and desired.


☐ A certified copy of a _____ application.☐ Information Disclosure Statement under 37 CFR 1.97.☐ A petition to extend time to respond in the parent application.☐ Notification of change of ☐ power of attorney ☐ correspondence address filed in prior application.

**In view of the Unsigned Declaration as filed with this application and pursuant to 37 CFR §1.53(f),
Applicant requests deferral of the filing fee until submission of the Missing Parts of Application.**

DO NOT CHARGE THE FILING FEE AT THIS TIME.

Telephone:
(415) 576-0200

Facsimile:
(415) 576-0300


Eugene Garrett-Wachowski
Reg. No.: 37,330
Attorneys for Applicant

SF 212419 v1

SF 212419 v1

JCS42 U.S. PTO
09/29/98
04/14/99

**NUCLEIC ACID SEQUENCES AND PROTEINS
ASSOCIATED WITH AGING**

Inventors:

Glenna C. Burner, a citizen of
the United States of America,
residing at 7516 55th Place, NE,
Seattle, Washington 98115.

Joseph P. Brown, a citizen of the United
Kingdom, residing at 411 West Prospect
Street, Seattle, Washington 98119.

Assignee:

LifeSpan BioSciences, Inc.

Entity Status:

Small

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
(415) 576-0200

NUCLEIC ACID SEQUENCES AND PROTEINS ASSOCIATED WITH AGING

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/081,887, filed April 15, 1998, which is incorporated herein by reference in its entirety for all purposes.

FIELD OF THE INVENTION

This invention relates to the discovery of nucleic acids and proteins associated with the aging processes, such as cell proliferation and senescence, and aging-related diseases, such as Werner Syndrome and Progeria. The identification of these aging-associated nucleic acids and proteins have diagnostic uses in detecting the aging status of a cell population as well as application for gene therapy and the delaying of the aging process.

BACKGROUND OF THE INVENTION

Normal human diploid cells have a finite potential for proliferative growth (Hayflick, L., *et al.*, *Exp. Cell Res.* 25:585 (1961); Hayflick, L., *Exp. Cell Res.* 37:614 (1965)). Indeed, under controlled conditions, *in vitro* cultured human cells can maximally proliferate only to about 80 cumulative population doublings. The proliferative potential of such cells has been found to be a function of the number of cumulative population doublings which the cell has undergone (Hayflick, L., *et al.*, *Exp. Cell Res.* 25:585 (1961); Hayflick, L., *et al.*, *Exp. Cell Res.* 37: 614 (1985)). This potential is also inversely proportional to the *in vivo* age of the cell donor (Martin, G. M., *et al.*, *Lab. Invest.* 23:86 (1979); Goldstein, S., *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 64:155 (1969); Schneider, E. L., *Proc. Natl. Acad. Sci. (U.S.A.)* 73:3584 (1976); LeGuilty, Y., *et al.*, *Gereontology* 19:303 (1973)).

Cells that have exhausted their potential for proliferative growth are said to have undergone "senescence." Cellular senescence *in vitro* is exhibited by morphological changes and is accompanied by the failure of a cell to respond to exogenous growth factors. Cellular senescence, thus, represents a loss of the proliferative potential of the cell.

Although a variety of theories have been proposed to explain the phenomenon of cellular

senescence *in vitro*, experimental evidence suggests that the age-dependent loss of proliferative potential may be the function of a genetic program (Orgel, L. E., *Proc. Natl. Acad. Sci. (U.S.A.)* 49:517 (1963); De Mars, R., *et al.*, *Human Genet.* 16:87 (1972); M. Buchwald, *Mutat. Res.* 44:401 (1977); Martin, G. M., *et al.*, *Amer. J. Pathol.* 74:137 (1974); Smith, J. R., *et al.*, *Mech. Age. Dev.* 13:387 (1980); Kirkwood, T. B. L., *et al.*, *Theor. Biol.* 53:481 (1975).

The prospect of reversing senescence and restoring the proliferative potential of cells has implications in many fields of endeavor. Many of the diseases of old age are associated with the loss of this potential. Moreover, the tragic disease, progeria, which is characterized by accelerated aging, is associated with the loss of proliferative potential of cells. Werner Syndrome and Hutchinson-Gilford Syndrome are two forms of progeria. A major clinical difference between the two is that the onset of Hutchinson-Gilford Syndrome (sometimes called progeria of childhood) occurs within the first decade of life, whereas the first evidence of Werner Syndrome (sometimes called progeria of adulthood) appears only after puberty, with the full symptoms becoming manifest in individuals 20 to 30 years old.

More particularly, Hutchinson-Gilford syndrome is a very rare progressive disorder of childhood characterized by premature aging (progeria), growth delays occurring in the first year of life resulting in short stature and low weight, deterioration of the layer of fat beneath the skin (subcutaneous adipose tissue), and characteristic craniofacial abnormalities, including an abnormally small face, underdeveloped jaw (micrognathia), unusually prominent eyes and/or a small, "beak-like" nose. In addition, during the first year or two of life, scalp hair, eyebrows and eyelashes may become sparse, and veins of the scalp may become unusually prominent. Additional symptoms and physical findings may include joint stiffness, repeated nonhealing fractures, a progressive aged appearance of the skin, delays in tooth eruption (dentition) and/or malformation and crowding of the teeth. Individuals with the disorder typically have normal intelligence. In most cases, affected individuals experience premature, widespread thickening and loss of elasticity of artery walls (arteriosclerosis), potentially resulting in life-threatening complications. Hutchinson-Gilford Progeria Syndrome is thought to be due to an autosomal dominant genetic change (mutation) that occurs for unknown reasons (sporadic).

Moreover, Werner Syndrome patients prematurely develop many age related diseases, including arteriosclerosis, malignant neoplasma, type II diabetes, osteoporosis,

ocular cataracts, early graying, loss of hair, skin atrophy and aged appearance. Although Werner Syndrome patients prematurely show some of the signs of aging (such as graying of the hair and hair loss, atherosclerosis, osteoporosis and type II diabetes mellitus), they fail to show others. For example, they exhibit no premature cognitive decline or Alzheimer's symptoms. In addition, they experience many symptoms not associated with normal aging (such as ulceration of the skin, particularly around the ankles, alteration of the vocal chords resulting in a high-pitched voice, and an absence of the growth spurt that normally occurs after puberty).

In view of the devastating effects of the aging process and age-related diseases, reversing senescence and restoring the proliferative potential of cells would have far-reaching implications for the treatment of these diseases, of other age-related disorders, and, of aging per se. In addition, the restoration of proliferative potential of cultured cells has uses in medicine and in the pharmaceutical industry. The ability to immortalize nontransformed cells can be used to generate an endless supply of certain tissues and also of cellular products.

SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acids and proteins associated with aging processes and aging-related diseases (*e.g.*, progeria and Werner Syndrome). In particular, sequences associated with senescence are provided. Such sequences can be used to determine the aging status of a cell population, *e.g.*, whether a cell is aging or is undergoing senescence. Moreover, the present invention provides sequences indicative of the proliferation state or youth of a cell. In addition, the present invention provides sequences associated with the aging of skin cells and, in particular, fibroblast cells. The isolated nucleic acids can be used to determine the aging status of a cell population. In addition, they can also be targeted and their level of expression altered by, for example, gene therapy methods (*e.g.*, by altering the subject sequences). Such methods can be used, for example, to slow or stop the aging process of the cell population; to arrest the growth of a proliferating cell population, such as a tumor cell population; to promote division in cells which are prematurely arrested; to determine that a cell population is healthy and rapidly dividing; and to determine that a cell population is not dividing and proliferating. Further, the present invention provides isolated nucleic acids associated with cyclin A.

In one aspect, an isolated nucleic acid is provided which comprises a polynucleotide sequence associated with the senescence of a cell, the polynucleotide sequence encoding a protein that specifically binds to antibodies raised against a protein encoded by SEQ ID NO:1. In one embodiment, the nucleic acid sequence has at least 85% sequence identity with SEQ ID NO:1. In another embodiment, the sequence has at least 95% sequence identity with SEQ ID NO:1. In still another embodiment, the isolated nucleic acid comprises a polynucleotide sequence associated with the senescence of a cell, the polynucleotide sequence being at least about 80% identical to a nucleic acid sequence as set forth in SEQ. ID. NO.:1 over a region that is at least about 32 nucleotides in length when compared using the BLASTIN algorithm with a Wordlength (W) of 11, M=5, Cutoff=100 and N=4. Moreover, the isolated nucleic acid sequence comprises a polynucleotide sequence which hybridizes to a nucleic acid having a sequence as shown in SEQ. ID. NO:1 under stringent conditions. In addition, the present invention provides isolated proteins encoded by this nucleic acid and antibodies which selectively bind to such proteins.

In another aspect, an isolated nucleic acid is provided which comprises a polynucleotide sequence associated with G_0 -arrested cells, the polynucleotide sequence encoding a protein that specifically binds to antibodies raised against a protein encoded by SEQ ID NO:2. In one embodiment, the nucleic acid sequence has at least 85% sequence identity with SEQ ID NO:2. In another embodiment, the sequence has at least 95% sequence identity with SEQ ID NO:2. In still another embodiment, the isolated nucleic acid comprises a polynucleotide sequence associated with G_0 -arrested cells, the polynucleotide sequence being at least about 80% identical to a nucleic acid sequence as set forth in SEQ. ID. NO.:2 over a region that is at least about 40 nucleotides in length when compared using the BLASTIN algorithm with a Wordlength (W) of 11, M=5, Cutoff=100 and N=4. Moreover, the isolated nucleic acid sequence comprises a polynucleotide sequence which hybridizes to a nucleic acid having a sequence as shown in SEQ. ID. NO:2 under stringent conditions. In addition, the present invention provides isolated proteins encoded by this nucleic acid and antibodies which selectively bind to such proteins.

In yet another aspect, the present invention provides a method for identifying a modulator of senescence of a cell, the method comprising: culturing the cell in the presence of said modulator to form a first cell culture; contacting RNA from the first cell culture with a probe which comprises a polynucleotide sequence associated with senescence;

and determining whether the amount of the probe which hybridizes to the RNA from the first cell culture is increased or decrease relative to the amount of the probe which hybridizes to RNA from a second cell culture grown in the absence of the modulator. In one embodiment of this method, the probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-157 and 168-175 or, alternatively, the probe can comprise a polynucleotide sequences that is substantially identical to SEQ. ID. NOS:2, 38-157 and 168-175. In a further embodiment of this method, the senescence can be associated with progeria and the probe can comprise at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-41. 139-152 and 171-173. In still a further embodiment of this method, the senescence can be associated with Werner syndrome and the probe can comprise at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:42-49, 134-138, 153-157 168-170.

In still another aspect, the present invention provides a method for detecting whether a cell is undergoing senescence, the method comprising: contacting RNA from the cell with a probe which comprises a polynucleotide sequence associated with senescence; and determining whether the amount of the probe which hybridizes to the RNA is increased or decrease relative to the amount of the probe which hybridizes to RNA from a non-senescent cell. In one embodiment of this method, the probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-157 and 168-175. As with the previous method, the senescence can be associated with progeria and the probe can comprise at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-41. 139-152 and 171-173. Moreover, the senescence can be associated with Werner syndrome and the probe can comprise at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:42-49, 134-138, 153-157 168-170.

In a further aspect, the present invention provides a method for identifying a modulator of a G_0 -arrested cell, the method comprising: culturing the cell in the presence of the modulator to form a first cell culture; contacting RNA from the first cell culture with a probe which comprises a polynucleotide sequence associated with G_0 -arrested cells; and determining whether the amount of the probe which hybridizes to the RNA from the first cell culture is increased or decrease relative to the amount of the probe which hybridizes to RNA

from a second cell culture grown in the absence of the modulator. In one embodiment of this method, the probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NO: 1 and SEQ. ID. NO:3 or, alternatively, the probe comprises a polynucleotide sequence that is substantially identical to a polynucleotide sequence selected from the group consisting of SEQ. ID. NO: 1 and SEQ. ID. NO:3.

In still a further aspect, the present invention provides a method for detecting whether a cell is G_0 -arrested, the method comprising: contacting RNA from the cell with a probe which comprises a polynucleotide sequence associated with G_0 -arrested cells; and determining whether the amount of the probe which hybridizes to the RNA is increased or decrease relative to the amount of the probe which hybridizes to RNA from a non- G_0 -arrested cell. As with the previous method, the probe, in one exemplar embodiment, comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NO: 1 and SEQ. ID. NO:3 or, alternatively, the probe comprises a polynucleotide sequence that is substantially identical to a polynucleotide sequence selected from the group consisting of SEQ. ID. NO: 1 and SEQ. ID. NO:3.

In still another aspect, the present invention provides a method for identifying a modulator of cyclin A, the method comprising: culturing a cell in the presence of the modulator to form a first cell culture; contacting RNA from the first cell culture with a probe which comprises a polynucleotide sequence associated with cyclin A; and determining whether the amount of the probe which hybridizes to the RNA from the first cell culture is increased or decrease relative to the amount of the probe which hybridizes to RNA from a second cell culture grown in the absence of the modulator. In one embodiment of this method, the probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:32-37 or, alternatively, the probe comprises a polynucleotide sequence that is substantially identical to a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:32-37.

In another aspect, the present invention provides a method for modulating cell senescence in a patient in need thereof, the method comprising administering to the patient a compound that modulates the senescence of a cell. In one embodiment, the compound increases or decreases the expression level of a nucleic acid associated with senescence. Within this embodiment, the nucleic acid comprises, for example, at least about 10

nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-157 and 168-175 or, alternatively, the nucleic acid is substantially identical to a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-157 and 168-175. In a further embodiment of this method, the senescence can be associated with progeria and the probe can comprise at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-41. 139-152 and 171-173. In still a further embodiment of this method, the senescence can be associated with Werner Syndrome and the probe can comprise at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:42-49, 134-138, 153-157 168-170. In this method, the compound can be, for example, an antisense molecule or a ribozyme.

In a further aspect, the present invention provides a method for detecting whether a fibroblast cell is aging, the method comprising: contacting RNA from the fibroblast cell with a probe which comprises a polynucleotide sequence associated with aging; and determining whether the amount of the probe which hybridizes to the RNA is increased or decrease relative to the amount of the probe which hybridizes to RNA from a non-aging fibroblast cell. In one embodiment of this method, the probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:158-164 and 176-178. Similarly, the present invention provides a method for modulating the aging of a fibroblast cell in a patient in need thereof, the method comprising administering to the patient a compound that modulates the aging of the fibroblast cell. In one embodiment, the compound increases or decreases the expression level of a nucleic acid associated with the aging of fibroblast cells. In this embodiment, the nucleic acid can, for example, comprise at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:158-164 and 176-178.

In still another aspect, the present invention provides a method for detecting whether a skin cell is aging, the method comprising: contacting RNA from skin cells with a probe which comprises a polynucleotide sequence associated with senescence; and determining whether the amount of the probe which hybridizes to the RNA is increased or decrease relative to the amount of the probe which hybridizes to RNA from a non-aging skin cell. In one embodiment of this method, the probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:165-

167 and 179. In addition, the present invention provides a method for modulating the aging of a skin cell in a patient in need thereof, the method comprising administering to the patient a compound that modulates the aging of the skin cell. In one embodiment, the compound increases or decreases the expression level of a nucleic acid associated with the aging of skin cells. In this embodiment, the nucleic acid can, for example, comprise at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:165-167 and 169.

In another aspect, the present invention provides a method for identifying a modulator of a young cell, the method comprising: culturing the cell in the presence of the modulator to form a first cell culture; contacting RNA from the first cell culture with a probe which comprises a polynucleotide sequence associated with young cells; and determining whether the amount of the probe which hybridizes to the RNA from the first cell culture is increased or decrease relative to the amount of the probe which hybridizes to RNA from a second cell culture grown in the absence of the modulator. In one embodiment of this method, the probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:4-31 and 124-133 or, alternatively, the probe comprises a polynucleotide sequences that is substantially identical to a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:4-31 and 124-133. In addition, the present invention provides a method for detecting whether a cell is young, the method comprising: contacting RNA from the cell with a probe which comprises a polynucleotide sequence associated with young cells; and determining whether the amount of the probe which hybridizes to the RNA is increased or decrease relative to the amount of the probe which hybridizes to RNA from a non-young cell.

In still another aspect, the present invention provides kits for carrying out the various methods. For instance, in one embodiment, a kit is provided for detecting whether a cell is undergoing senescence, the kit comprising: a probe which comprises a polynucleotide sequence associated with senescence; and a label for detecting the presence of the probe. In one embodiment, the probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-157 and 168-175. Additionally, this kit can further comprise a plurality of probes each of which comprises a polynucleotide sequence associated with senescence; and a label or labels for detecting the presence of the plurality of probes. The probes can optionally be immobilized on a solid

support (*e.g.*, a chip). Similarly, the present invention provides kits for detecting whether a cell is G_0 -arrested, for detecting whether a skin cell is aging, for detecting whether a cell is young (*e.g.*, proliferating or non-proliferating), for detecting whether a fibroblast is aging, *etc.*

The polypeptide of the present invention can be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide. The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

This invention also includes isolated proteins which are encoded by the nucleic acids and the genes associated with them which are indicative of senescence or healthy dividing cells depending upon the sequence of interest.

This invention further provides for methods of detecting the presence of the proteins in human tissue, the methods comprising: (i) isolating a biological sample from a human being tested for the proteins of interest; (ii) contacting the biological sample with a target-specific reagent; and (iii) detecting the level of the target protein specific reagent that selectively associates with the sample. Such methods are contemplated for a variety of different purposes including detection of cell deterioration, premature onset of aging arising in any tissue, *etc.* Such methods include nucleic acid hybridization technology, amplification of nucleic acid technology and immunoassays.

The invention also embraces the use of antisense methods for studying aging in animals and cells. Typically, any time a gene is identified, it can be studied by knocking out the gene in an animal and observing the effect on the animal phenotype. Knockouts can be achieved by transposons which insert by homologous recombinations, antisense or ribozymes specifically directed at disturbing the embryonic stem cells of an organism such as a mouse. Ribozymes can include any of the various types of ribozymes modified to cleave the mRNA encoding, for example, the senescent-associated protein. Examples include hairpins and hammerhead ribozymes. Finally, antisense molecules which selectively bind, for example, to the senescent protein mRNA are expressed via expression cassettes operably linked to subsequences of the senescent protein gene and generally comprise 20-50 base long sequences in opposite orientation to the mRNA to which they are targeted.

DEFINITIONS

"Amplification" primers are oligonucleotides comprising either natural or analog nucleotides that can serve as the basis for the amplification of a select nucleic acid sequence. They include, for example, both polymerase chain reaction primers and ligase chain reaction oligonucleotides.

"Antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen). The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, *e.g.*, as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce $F(ab')_2$, a dimer of Fab which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The $F(ab')_2$ may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the $F(ab')_2$ dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region (*see, Fundamental Immunology*, Third Edition, W.E. Paul, ed., Raven Press, N.Y. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized *de novo* using recombinant DNA methodologies (*e.g.*, single chain Fv).

"Associated" in the context of senescence refers to the relationship of the relevant nucleic acids and their expression, or lack thereof, to the onset of senescence in the subject cell. For example, senescence can be associated with expression of a particular gene that is not expressed, or is expressed at a lower level, in a non-senescent cell. Conversely, a senescence-associated gene can be one that is not expressed in a senescent cell (or a cell undergoing senescence), or is expressed at a lower level in the senescent cell than in a non-senescent cell.

"Biological samples" refers to any tissue or liquid sample having genomic DNA or other nucleic acids (*e.g.*, mRNA) or proteins. It includes both cells with a normal complement of chromosomes and cells suspected of senescence.

"Competent to discriminate between the wild type gene and the mutant form" means a hybridization probe or primer sequence that allows the trained artisan to detect the presence or absence of base changes, deletions or additions to the nucleotide sequence of interest. A probe sequence is a sequence containing the site that is changed, deleted or added to. A primer sequence will hybridize with the sequences surrounding or flanking the base changes, deletions or additions and, using the gene sequence as template, allow the further synthesis of nucleotide sequences that contain the base changes or additions. In addition, the probe may act as a primer. It is important to point out that this invention allows for the design of PCR primers capable of amplifying entire exons. To achieve this, primers need hybridize with intron sequences. This invention provides such intron sequences.

The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

A "heterologous sequence" or a "heterologous nucleic acid," as used herein, is one that originates from a source foreign to the particular host cell, or, if from the same source, is modified from its original form. Thus, a heterologous gene associated with senescence in a host cell includes a senescence-associated gene that is endogenous to the particular host cell, but has been modified. Modification of the heterologous sequence may occur, *e.g.*, by treating the DNA with a restriction enzyme to generate a DNA fragment that is capable of being operably linked to the promoter. Techniques such as site-directed mutagenesis are also useful for modifying a heterologous sequence.

The term "isolated," when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It is preferably in a homogeneous state although it can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein which is the predominant species present in a preparation is substantially purified. In particular, an isolated gene is separated from open reading frames which flank the gene and encode a protein other than the gene of interest. The term "purified" denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure.

"Non-proliferating cells" are those which are said to be in a G_0 -phase where the cells are in a resting stage of arrested growth at the G_0 phase, usually because they are deprived of an essential nutrient and cannot grow exponentially.

The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides which have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (*e.g.*, degenerate codon substitutions) and complementary sequences and as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer *et al.*, *Nucleic Acid Res.* 19:5081 (1991); Ohtsuka *et al.*, *J. Biol. Chem.* 260:2605-2608 (1985); and Cassol *et al.*, 1992; Rossolini *et al.*, *Mol. Cell. Probes* 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.

"Nucleic acid derived from a gene" refers to a nucleic acid for whose synthesis the gene, or a subsequence thereof, has ultimately served as a template. Thus, an mRNA, a cDNA reverse transcribed from an mRNA, an RNA transcribed from that cDNA, a DNA amplified from the cDNA, an RNA transcribed from the amplified DNA, *etc.*, are all

derived from the gene and detection of such derived products is indicative of the presence and/or abundance of the original gene and/or gene transcript in a sample.

As used herein a "nucleic acid probe" is defined as a nucleic acid capable of binding to a target nucleic acid (e.g., a nucleic acid associated with cell senescence) of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, for example, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions.

Nucleic acid probes can be DNA or RNA fragments. DNA fragments can be prepared, for example, by digesting plasmid DNA, or by use of PCR, or synthesized by either the phosphoramidite method described by Beaucage and Carruthers, *Tetrahedron Lett.* 22:1859-1862 (1981) (Beaucage and Carruthers), or by the triester method according to Matteucci, *et al.*, *J. Am. Chem. Soc.*, 103:3185 (1981) (Matteucci), both incorporated herein by reference. A double stranded fragment may then be obtained, if desired, by annealing the chemically synthesized single strands together under appropriate conditions, or by synthesizing the complementary strand using DNA polymerase with an appropriate primer sequence. Where a specific sequence for a nucleic acid probe is given, it is understood that the complementary strand is also identified and included. The complementary strand will work equally well in situations where the target is a double-stranded nucleic acid.

A "labeled nucleic acid probe" is a nucleic acid probe that is bound, either covalently, through a linker, or through ionic, van der Waals or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe.

The term "target nucleic acid" refers to a nucleic acid (often derived from a biological sample) to which a nucleic acid probe is designed to specifically hybridize. It is either the presence or absence of the target nucleic acid that is to be detected, or the amount of the target nucleic acid that is to be quantified. The target nucleic acid has a sequence that

is complementary to the nucleic acid sequence of the corresponding probe directed to the target. The term target nucleic acid may refer to the specific subsequence of a larger nucleic acid to which the probe is directed or to the overall sequence (e.g., gene or mRNA) whose expression level it is desired to detect. The difference in usage will be apparent from context.

The phrase "a nucleic acid sequence encoding" refers to a nucleic acid which contains sequence information for a structural RNA such as rRNA, a tRNA, or the primary amino acid sequence of a specific protein or peptide, or a binding site for a trans-acting regulatory agent. This phrase specifically encompasses degenerate codons (*i.e.*, different codons which encode a single amino acid) of the native sequence or sequences which may be introduced to conform with codon preference in a specific host cell.

The term "operably linked" refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, signal sequence, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence affects transcription and/or translation of the nucleic acid corresponding to the second sequence.

"Proliferating cells" are those which are actively undergoing cell division and grow exponentially.

The term "recombinant" when used with reference to a cell indicates that the cell replicates a heterologous nucleic acid, or expresses a peptide or protein encoded by a heterologous nucleic acid. Recombinant cells can contain genes that are not found within the native (non-recombinant) form of the cell. Recombinant cells can also contain genes found in the native form of the cell wherein the genes are modified and re-introduced into the cell by artificial means. The term also encompasses cells that contain a nucleic acid endogenous to the cell that has been modified without removing the nucleic acid from the cell; such modifications include those obtained by gene replacement, site-specific mutation, and related techniques.

A "recombinant expression cassette" or simply an "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with nucleic acid elements that are capable of effecting expression of a structural gene in hosts compatible with such sequences. Expression cassettes include at least promoters and, optionally, transcription termination signals. Typically, the recombinant expression cassette includes a nucleic acid

to be transcribed (*e.g.*, a nucleic acid encoding a desired polypeptide), and a promoter. Additional factors necessary or helpful in effecting expression may also be used as described herein. For example, an expression cassette can also include nucleotide sequences that encode a signal sequence that directs secretion of an expressed protein from the host cell.

5 Transcription termination signals, enhancers, and other nucleic acids that influence gene expression, can also be included in an expression cassette.

The terms "identical" or percent "identity," in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.

10 The phrase "substantially identical," in the context of two nucleic acids or polypeptides, refers to two or more sequences or subsequences that have at least 60%, preferably 80%, most preferably 90-95% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Preferably, the substantial identity exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues. In a most preferred embodiment, the sequences are substantially identical over the entire length of the coding regions.

20 For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

25 Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and

30

TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (*see, generally, Ausubel et al., supra*).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al., supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters

M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, $M=5$, $N=-4$, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)).

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability ($P(N)$), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

Another indication that two nucleic acids are substantially identical is that the two molecules hybridize to each other under stringent conditions. The phrase "hybridizing specifically to," refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA. "Bind(s) substantially" refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.

"Stringent hybridization conditions" and "stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments, such as Southern and northern hybridizations, are sequence dependent, and are different under different

environmental parameters. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes*, part I, chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays," Elsevier, NY. Generally, highly stringent hybridization and wash conditions are selected to be about 5° C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. Typically, under "stringent conditions," a probe will hybridize to its target subsequence, but to no other sequences.

The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the T_m for a particular probe. An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formamide with 1 mg of heparin at 42°C, with the hybridization being carried out overnight. An example of highly stringent wash conditions is 0.15M NaCl at 72°C for about 15 minutes. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see*, Sambrook, *supra*, for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example medium stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 1x SSC at 45°C for 15 minutes. An example low stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 4-6x SSC at 40°C for 15 minutes. For short probes (*e.g.*, about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3, and the temperature is typically at least about 30°C. Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. In general, a signal to noise ratio of 2x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization. Nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

A further indication that two nucleic acids or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross

reactive with, or specifically binds to, the polypeptide encoded by the second nucleic acid. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions.

The phrase "specifically (or selectively) binds to an antibody" or "specifically (or selectively) immunoreactive with", when referring to a protein or peptide, refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the protein with the amino acid sequence encoded by any of the polynucleotides of the invention can be selected to obtain antibodies specifically immunoreactive with that protein and not with other proteins except for polymorphic variants. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays, Western blots, or immunohistochemistry are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See, Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York ("Harlow and Lane") for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. Typically, a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

A "conservative substitution," when describing a protein, refers to a change in the amino acid composition of the protein that does not substantially alter the protein's activity. Thus, "conservatively modified variations" of a particular amino acid sequence refers to amino acid substitutions of those amino acids that are not critical for protein activity or substitution of amino acids with other amino acids having similar properties (*e.g.*, acidic, basic, positively or negatively charged, polar or non-polar, *etc.*) such that the substitutions of even critical amino acids do not substantially alter activity. Conservative substitution tables providing functionally similar amino acids are well known in the art. See, also, Creighton (1984) *Proteins*, W.H. Freeman and Company. In addition, individual substitutions,

deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence are also "conservatively modified variations".

A "subsequence" refers to a sequence of nucleic acids or amino acids that comprise a part of a longer sequence of nucleic acids or amino acids (e.g., polypeptide) respectively.

DETAILED DESCRIPTION AND PREFERRED EMBODIMENTS OF THE INVENTION

The present invention provides nucleic acids and proteins that are indicative of aging or cell death (senescence) and cell proliferation. Host cells, vectors, and probes are described, as are antibodies to the proteins and uses of the proteins as antigens. The present invention provides methods for obtaining and expressing nucleic acids, methods for purifying gene products, other methods that can be used to detect and quantify the expression and quality of the gene product (e.g., proteins), and uses for both the nucleic acids and the gene products.

Cloning and Expression of the Nucleic Acids

A. General Recombinant DNA Methods.

This invention relies on routine techniques in the field of recombinant genetics. A basic text disclosing the general methods of use in this invention is Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Publish., Cold Spring Harbor, NY 2nd ed. (1989) and Kriegler, *Gene Transfer and Expression: A Laboratory Manual*, W.H. Freeman, N.Y., (1990), which are both incorporated herein by reference. Unless otherwise stated all enzymes are used in accordance with the manufacturer's instructions.

Nucleotide sizes are given in either kilobases (Kb) or base pairs (bp). These are estimates derived from agarose or acrylamide gel electrophoresis or, alternatively, from published DNA sequences.

Oligonucleotides that are not commercially available can be chemically synthesized according to the solid phase phosphoramidite triester method first described by S.L. Beaucage and M.H. Caruthers, *Tetrahedron Letts.*, 22(20):1859-1862 (1981), using an automated synthesizer, as described in D.R. Needham Van Devanter *et. al.*, *Nucleic Acids Res.*, 12:6159-6168, 1984. Purification of oligonucleotides is, for example, by either native

acrylamide gel electrophoresis or by anion-exchange HPLC as described in J.D. Pearson and F.E. Reanier, *J. Chrom.*, 255:137-149, 1983.

The nucleic acids described here, or fragments thereof, can be used as a hybridization probe for a cDNA library to isolate the corresponding full length cDNA and to isolate other cDNAs which have a high sequence similarity to the gene or similar biological activity. Probes of this type preferably have at least 30 bases and may contain, for example, 50 or more bases. The probe may also be used to identify a cDNA clone corresponding to a full length transcript and a genomic clone or clones that contain the complete gene including regulatory and promoter regions, exons and introns. An example of such a screen includes isolating the coding region of the gene by using the known DNA sequence to synthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary to that of the nucleic acids of the present invention can be used to screen a library of human cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

The sequence of the cloned genes and synthetic oligonucleotides can be verified using the chemical degradation method of A.M. Maxam *et al.*, *Methods in Enzymology*, 65:499-560, (1980). The sequence can be confirmed after the assembly of the oligonucleotide fragments into the double-stranded DNA sequence using the method of Maxam and Gilbert, *supra*, or the chain termination method for sequencing double-stranded templates of R.B. Wallace *et al.*, *Gene*, 16:21-26, 1981. Southern blot hybridization techniques can be carried out according to Southern *et al.*, *J. Mol. Biol.*, 98:503, 1975.

B. Cloning Methods for the Isolation of Nucleotide Sequences Encoding the Desired Proteins

In general, the nucleic acids encoding the subject proteins are cloned from DNA sequence libraries that are made to encode copy DNA (cDNA) or genomic DNA. The particular sequences can be located by hybridizing with an oligonucleotide probe, the sequence of which can be derived from the sequence listing provided herein, which provides a reference for PCR primers and defines suitable regions for isolating aging and senescent-associated specific probes. Alternatively, where the sequence is cloned into an expression library, the expressed recombinant protein can be detected immunologically with antisera or purified antibodies made against senescent protein.

To make the cDNA library, one should choose a source that is rich in mRNA. The mRNA can then be made into cDNA, ligated into a recombinant vector, and transfected

into a recombinant host for propagation, screening and cloning. Methods for making and screening cDNA libraries are well known. *See*, Gubler, U. and Hoffman, B.J., *Gene* 25:263-269, 1983 and Sambrook, *supra*.

For a genomic library, the DNA is extracted from the tissue and either mechanically sheared or enzymatically digested to yield fragments of preferably about 5-100 kb. The fragments are then separated by gradient centrifugation from undesired sizes and are constructed in bacteriophage lambda vectors. These vectors and phage are packaged *in vitro*, as described in Sambrook. Recombinant phage are analyzed by plaque hybridization as described in Benton and Davis, *Science*, 196:180-182 (1977). Colony hybridization is carried out as generally described in M. Grunstein *et al.*, *Proc. Natl. Acad. Sci. USA*, 72:3961-3965 (1975).

An alternative method combines the use of synthetic oligonucleotide primers with polymerase extension on an mRNA or DNA template. This polymerase chain reaction (PCR) method amplifies nucleic acids of the protein directly from mRNA, from cDNA, from genomic libraries or cDNA libraries. Restriction endonuclease sites can be incorporated into the primers. Polymerase chain reaction or other *in vitro* amplification methods may also be useful, for example, to clone nucleic acids that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of senescent encoding mRNA in physiological samples, for nucleic acid sequencing, or for other purposes. U.S. Patent Nos. 4,683,195 and 4,683,202 describe this method. Genes amplified by the PCR reaction can be purified from agarose gels and cloned into an appropriate vector.

Appropriate primers and probes for identifying the genes encoding aging-related senescent protein from alternative mammalian tissues are generated from comparisons of the sequences provided herein. For a general overview of PCR, *see PCR Protocols: A Guide to Methods and Applications*. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), *Academic Press*, San Diego (1990), incorporated herein by reference.

Synthetic oligonucleotides can be used to construct genes. This is done using a series of overlapping oligonucleotides, usually 40-120 bp in length, representing both the sense and nonsense strands of the gene. These DNA fragments are then annealed, ligated and cloned.

The gene for the onset of senescence or for cell proliferation, for example, is cloned using intermediate vectors before transformation into mammalian cells for

expression. These intermediate vectors are typically prokaryote vectors or shuttle vectors. The proteins can be expressed in either prokaryotes or eukaryotes.

C. Expression in Prokaryotes

To obtain high level expression of a cloned gene, such as those cDNAs encoding aging-related proteins in a prokaryotic system, it is essential to construct expression plasmids which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. Examples of regulatory regions suitable for this purpose in *E. coli* are the promoter and operator region of the *E. coli* tryptophan biosynthetic pathway as described by Yanofsky, C., *J. Bacteriol.*, 158:1018-1024 (1984), and the leftward promoter of phage lambda (P_L) as described by Herskowitz, I. and Hagen, D., *Ann. Rev. Genet.*, 14:399-445 (1980).

D. Expression in Eukaryotes

Standard eukaryotic transfection methods are used to produce mammalian, yeast or insect cell lines which express large quantities of the senescent protein which are then purified using standard techniques. See, e.g., Colley *et al.*, *J. Biol. Chem.* 264:17619-17622, (1989), and Guide to Protein Purification, in Vol. 182 of *Methods in Enzymology* (Deutscher ed., 1990), both of which are incorporated herein by reference.

Transformations of eukaryotic cells are performed according to standard techniques as described by D.A. Morrison, *J. Bact.*, 132:349-351 (1977), or by J.E. Clark-Curtiss and R. Curtiss, *Methods in Enzymology*, 101:347-362, Eds. R. Wu *et al.*, Academic Press, New York (1983).

Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see Sambrook *et al.*, *supra*). It is only necessary that the particular genetic engineering procedure utilized be capable of successfully introducing at least one gene into the host cell which is capable of expressing the protein.

The particular eukaryotic expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic cells may be used. Expression vectors containing regulatory elements from eukaryotic viruses are typically used. SV40 vectors include pSVT7 and pMT2. Vectors derived from bovine papilloma virus include pBV-1MTHA, and vectors derived from Epstein Bar virus include pHEBO, and p2O5. Other exemplary vectors include pMSG, pAV009/A⁺, pMTO10/A⁺, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV-40 early promoter, SV-40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

The vectors usually include selectable markers which result in gene amplification such as thymidine kinase, aminoglycoside phosphotransferase, hygromycin B phosphotransferase, xanthine-guanine phosphoribosyl transferase, CAD (carbamyl phosphate synthetase, aspartate transcarbamylase, and dihydroorotase), adenosine deaminase, dihydrofolate reductase, and asparagine synthetase and ouabain selection. Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with a target protein encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.

The expression vector of the present invention will typically contain both prokaryotic sequences that facilitate the cloning of the vector in bacteria as well as one or more eukaryotic transcription units that are expressed only in eukaryotic cells, such as mammalian cells. The vector may or may not comprise a eukaryotic replicon. If a eukaryotic replicon is present, then the vector is amplifiable in eukaryotic cells using the appropriate selectable marker. If the vector does not comprise a eukaryotic replicon, no episomal amplification is possible. Instead, the transfected DNA integrates into the genome of the transfected cell, where the promoter directs expression of the desired gene. The expression vector is typically constructed from elements derived from different, well characterized viral or mammalian genes. For a general discussion of the expression of cloned genes in cultured mammalian cells, see, Sambrook *et al.*, *supra*, Ch. 16.

The prokaryotic elements that are typically included in the mammalian expression vector include a replicon that functions in *E. coli*, a gene encoding antibiotic

resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The particular antibiotic resistance gene chosen is not critical, any of the many resistance genes known in the art are suitable. The prokaryotic sequences are preferably chosen such that they do not interfere with the replication of the DNA in eukaryotic cells.

The expression vector contains a eukaryotic transcription unit or expression cassette that contains all the elements required for the expression of the senescent protein encoding DNA in eukaryotic cells. A typical expression cassette contains a promoter operably linked to the DNA sequence encoding the senescent protein and signals required for efficient polyadenylation of the transcript. The DNA sequence encoding the protein may typically be linked to a cleavable signal peptide sequence to promote secretion of the encoded protein by the transformed cell. Such signal peptides would include, among others, the signal peptides from tissue plasminogen activator, insulin, and neuron growth factor, and juvenile hormone esterase of *Heliothis virescens*. Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

Eukaryotic promoters typically contain two types of recognition sequences, the TATA box and upstream promoter elements. The TATA box, located 25-30 base pairs upstream of the transcription initiation site, is thought to be involved in directing RNA polymerase to begin RNA synthesis. The other upstream promoter elements determine the rate at which transcription is initiated.

Enhancer elements can stimulate transcription up to 1,000 fold from linked homologous or heterologous promoters. Enhancers are active when placed downstream or upstream from the transcription initiation site. Many enhancer elements derived from viruses have a broad host range and are active in a variety of tissues. For example, the SV40 early gene enhancer is suitable for many cell types. Other enhancer/promoter combinations that are suitable for the present invention include those derived from polyoma virus, human or murine cytomegalovirus, the long term repeat from various retroviruses such as murine leukemia virus, murine or Rous sarcoma virus and HIV. See, *Enhancers and Eukaryotic Expression*, Cold Spring Harbor Pres, Cold Spring Harbor, N.Y. 1983, which is incorporated herein by reference.

In the construction of the expression cassette, the promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

If the mRNA encoded by the structural gene is to be efficiently translated, polyadenylation sequences are also commonly added to the vector construct. Two distinct sequence elements are required for accurate and efficient polyadenylation: GU or U rich sequences located downstream from the polyadenylation site and a highly conserved sequence of six nucleotides, AAUAAA, located 11-30 nucleotides upstream. Termination and polyadenylation signals that are suitable for the present invention include those derived from SV40, or a partial genomic copy of a gene already resident on the expression vector.

In addition to the elements already described, the expression vector of the present invention may typically contain other specialized elements intended to increase the level of expression of cloned genes or to facilitate the identification of cells that carry the transfected DNA. For instance, a number of animal viruses contain DNA sequences that promote the extra chromosomal replication of the viral genome in permissive cell types. Plasmids bearing these viral replicons are replicated episomally as long as the appropriate factors are provided by genes either carried on the plasmid or with the genome of the host cell.

1. Expression in Yeast.

Synthesis of heterologous proteins in yeast is well known and described. *Methods in Yeast Genetics*, Sherman, F., et al., Cold Spring Harbor Laboratory, (1982) is a well recognized work describing the various methods available to produce senescent protein in yeast.

For high level expression of a gene in yeast, it is essential to connect the gene to a strong promoter system as in the prokaryote and also to provide efficient transcription termination/polyadenylation sequences from a yeast gene. Examples of useful promoters

include GAL10 (Johnson, M., and Davies, R.W., *Mol. and Cell. Biol.*, 4:1440-1448 (1984)) ADH2 (Russell, D., *et al.*, *J. Biol. Chem.*, 258:2674-2682, (1983)), PHO5 (*EMBO J.* 6:675-680, (1982)), and MF α 1. A multicopy plasmid with a selective marker such as Leu-2, URA-3, Trp-1, and His-3 is also desirable.

The MF α 1 promoter is preferred for expression of the subject protein in yeast. The MF α 1 promoter, in a host of the α mating-type, is constitutive, but is switched off in diploids or cells with the α mating-type. It can, however, be regulated by raising or lowering the temperature in hosts which have a ts mutation at one of the SIR loci. The effect of such a mutation at 35°C on an α -type cell is to turn on the normally silent gene coding for the α mating-type. The expression of the silent α mating-type gene, in turn, turns off the MF α 1 promoter. Lowering the temperature of growth to 27°C reverses the whole process, *i.e.*, turns the α mating-type off and turns the MF α 1 on (Herskowitz, I. and Oshima, Y., in *The Molecular Biology of the Yeast Saccharomyces*, (eds. Strathern, J.N. Jones, E.W., and Broach, J.R., Cold Spring Harbor Lab., Cold Spring Harbor, N.Y., pp.181-209 (1982)).

The polyadenylation sequences are provided by the 3'-end sequences of any of the highly expressed genes, like ADHI, MF α 1, or TPI (Alber, T. and Kawasaki, G., *J. of Mol. & Appl. Genet.* 1:419-434 (1982)).

A number of yeast expression plasmids like YEp6, YEpl3, YEp4 can be used as vectors. A gene of interest can be fused to any of the promoters in various yeast vectors. The above-mentioned plasmids have been fully described in the literature (Botstein, *et al.*, 1979, *Gene*, 8:17-24 (1979); Broach, *et al.*, *Gene*, 8:121-133 (1979)).

Two procedures are used in transforming yeast cells. In one case, yeast cells are first converted into protoplasts using zymolyase, lyticase or glucylase, followed by addition of DNA and polyethylene glycol (PEG). The PEG-treated protoplasts are then regenerated in a 3% agar medium under selective conditions. Details of this procedure are given in the papers by J.D. Beggs, *Nature* (London), 275:104-109, (1978); and Hinnen, A., *et al.*, *Proc. Natl. Acad. Sci. USA*, 75:1929-1933, (1978). The second procedure does not involve removal of the cell wall. Instead, the cells are treated with lithium chloride or acetate and PEG and put on selective plates (Ito, H., *et al.*, *J. Bact.*, 153:163-168 (1983)).

The protein can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification

process can be accomplished by using, for example, Western blot techniques or radioimmunoassays.

2. Expression in insect cells

The baculovirus expression vector utilizes the highly expressed and regulated *Autographa californica* nuclear polyhedrosis virus (AcMNPV) polyhedrin promoter modified for the insertion of foreign genes. Synthesis of polyhedrin protein results in the formation of occlusion bodies in the infected insect cell. The recombinant proteins expressed using this vector have been found in many cases to be antigenically, immunogenically and functionally similar to their natural counterparts. In addition, the baculovirus vector utilizes many of the protein modification, processing, and transport systems that occur in higher eukaryotic cells.

Briefly, the DNA sequence encoding, for example, the senescent protein is inserted into a transfer plasmid vector in the proper orientation downstream from the polyhedrin promoter, and flanked on both ends with baculovirus sequences. Cultured insect cell, commonly *Spodoptera frugiperda*, are transfected with a mixture of viral and plasmid DNAs. The virus that develop, some of which are recombinant virus that result from homologous recombination between the two DNAs, are plated at 100-1000 plaques per plate. The plaques containing recombinant virus can be identified visually because of their ability to form occlusion bodies or by DNA hybridization. The recombinant virus is isolated by plaque purification. The resulting recombinant virus, capable of expressing, for example, senescent protein, is self propagating in that no helper virus is required for maintenance or replication. After infecting an insect culture with recombinant virus, one can expect to find recombinant protein within 48-72 hours. The infection is essentially lytic within 4-5 days.

There are a variety of transfer vectors into which the nucleotides of the invention can be inserted. For a summary of transfer vectors, *see*, Luckow, V.A. and M.D. Summers, *Bio/Technology*, 6:47-55 (1988). Preferred is the transfer vector pAcUW21 described by Bishop, D.H.L. in *Seminars in Virology*, 3:253-264 (1992).

3. Expression in recombinant vaccinia virus-infected cells.

The gene encoding, for example, a senescent protein is inserted into a plasmid designed for producing recombinant vaccinia, such as pGS62, Langford, C.L., *et al.*, *Mol. Cell. Biol.* 6:3191-3199, (1986). This plasmid consists of a cloning site for insertion of

foreign genes, the P7.5 promoter of vaccinia to direct synthesis of the inserted gene, and the vaccinia TK gene flanking both ends of the foreign gene.

When the plasmid containing the desired nucleotide sequence is constructed, the gene can be transferred to vaccinia virus by homologous recombination in the infected cell. To achieve this, suitable recipient cells are transfected with the recombinant plasmid by standard calcium phosphate precipitation techniques into cells already infected with the desirable strain of vaccinia virus, such as Wyeth, Lister, WR or Copenhagen. Homologous recombination occurs between the TK gene in the virus and the flanking TK gene sequences in the plasmid. This results in a recombinant virus with the foreign gene inserted into the viral TK gene, thus rendering the TK gene inactive. Cells containing recombinant viruses are selected by adding medium containing 5-bromodeoxyuridine, which is lethal for cells expressing a TK gene.

Confirmation of production of recombinant virus can be achieved by DNA hybridization using cDNA encoding, for example, the senescent protein and by immunodetection techniques using antibodies specific for the expressed protein. Virus stocks may be prepared by infection of cells such as HeLa S3 spinner cells and harvesting of virus progeny.

4. Expression in cell cultures

The protein cDNA of the invention can be ligated to various expression vectors for use in transforming host cell cultures. The vectors typically contain gene sequences to initiate transcription and translation of the senescent gene. These sequences need to be compatible with the selected host cell. In addition, the vectors preferably contain a marker to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or metallothionein. Additionally, a vector might contain a replicative origin.

Cells of mammalian origin are illustrative of cell cultures useful for the production of, for example, the senescent protein. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. Illustrative examples of mammalian cell lines include VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, WI38, BHK, COS-7 or MDCK cell lines. NIH 3T3 or COS cells are preferred.

As indicated above, the vector, *e.g.*, a plasmid, which is used to transform the host cell, preferably contains DNA sequences to initiate transcription and sequences to control the translation of the senescent protein gene sequence. These sequences are referred to as expression control sequences. Illustrative expression control sequences are obtained from the SV-40 promoter (*Science*, 222:524-527 (1983)), the CMV I.E. Promoter (*Proc. Natl. Acad. Sci.* 81:659-663 (1984)) or the metallothionein promoter (*Nature* 296:39-42 (1982)). The cloning vector containing the expression control sequences is cleaved using restriction enzymes and adjusted in size as necessary or desirable and ligated with sequences encoding senescent protein by means well known in the art.

As with yeast, when higher animal host cells are employed, polyadenylation or transcription terminator sequences from known mammalian genes need to be incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, J. *et al.*, *J. Virol.* 45: 773-781, (1983)).

Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M., "*Bovine Papilloma virus DNA a Eukaryotic Cloning Vector*" in *DNA Cloning Vol.II a Practical Approach* Ed. D.M. Glover, IRL Press, Arlington, Virginia pp. 213-238, (1985).

The transformed cells are cultured by means well known in the art. For example, such means are published in *Biochemical Methods in Cell Culture and Virology*, Kuchler, R.J., Dowden, Hutchinson and Ross, Inc. (1977). The expressed protein is isolated from cells grown as suspensions or as monolayers. The latter are recovered by well known mechanical, chemical or enzymatic means.

Purification of the Proteins of the Invention

After expression, the proteins of the present invention can be purified to substantial purity by standard techniques, including selective precipitation with substances as ammonium sulfate; column chromatography, immunopurification methods, and others. *See*, for instance, R. Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag: New

York (1982), U.S. Patent No. 4,673,641, Ausubel, and Sambrook, incorporated herein by reference.

A number of conventional procedures can be employed when recombinant protein is being purified. For example, proteins having established molecular adhesion properties can be reversibly fused to the subject protein. With the appropriate ligand, the senescent protein, for example, can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein is then removed by enzymatic activity. Finally, senescent protein can be purified using immunoaffinity columns.

A. Purification of Proteins from Recombinant Bacteria

When recombinant proteins are expressed by the transformed bacteria in large amounts, typically after promoter induction, but expression can be constitutive, the proteins may form insoluble aggregates. There are several protocols that are suitable for purification of protein inclusion bodies. For example, purification of aggregate proteins (hereinafter referred to as inclusion bodies) typically involves the extraction, separation and/or purification of inclusion bodies by disruption of bacterial cells, typically but not limited by, incubation in a buffer of about 100-150 µg/mL lysozyme and 0.1% Nonidet P40, a non-ionic detergent. The cell suspension can be ground using a Polytron grinder (Brinkman Instruments, Westbury, N.Y.). Alternatively, the cells can be sonicated on ice. Alternate methods of lysing bacteria are described in Ausubel and Sambrook and will be apparent to those of skill in the art.

The cell suspension is generally centrifuged and the pellet containing the inclusion bodies resuspended in buffer which does not dissolve but washes the inclusion bodies, *e.g.*, 20 mM Tris-HCl (pH 7.2), 1 mM EDTA, 150 mM NaCl and 2% Triton-X 100, a non-ionic detergent. It may be necessary to repeat the wash step to remove as much cellular debris as possible. The remaining pellet of inclusion bodies may be resuspended in an appropriate buffer (*e.g.*, 20 mM sodium phosphate, pH 6.8, 150 mM NaCl). Other appropriate buffers will be apparent to those of skill in the art.

Following the washing step, the inclusion bodies are solubilized by the addition of a solvent that is both a strong hydrogen acceptor and a strong hydrogen donor (or a combination of solvents each having one of these properties); the proteins that formed the

inclusion bodies may then be renatured by dilution or dialysis with a compatible buffer. Suitable solvents include, but are not limited to, urea (from about 4 M to about 8 M), formamide (at least about 80%, volume/volume basis), and guanidine hydrochloride (from about 4 M to about 8 M). Some solvents which are capable of solubilizing aggregate-forming proteins, such as SDS (sodium dodecyl sulfate) and 70% formic acid, are inappropriate for use in this procedure due to the possibility of irreversible denaturation of the proteins, accompanied by a lack of immunogenicity and/or activity. Although guanidine hydrochloride and similar agents are denaturants, this denaturation is not irreversible and renaturation may occur upon removal (by dialysis, for example) or dilution of the denaturant, allowing re-formation of immunologically and/or biologically active protein of interest. After solubilization, the protein can be separated from other bacterial proteins by standard separation techniques.

Alternatively, it is possible to purify protein from bacteria periplasm. Where protein is exported into the periplasm of the bacteria, the periplasmic fraction of the bacteria can be isolated by cold osmotic shock in addition to other methods known to skill in the art (see, Ausubel, *supra*).

To isolate recombinant proteins from the periplasm, the bacterial cells are centrifuged to form a pellet. The pellet is resuspended in a buffer containing 20% sucrose. To lyse the cells, the bacteria are centrifuged and the pellet is resuspended in ice-cold 5 mM MgSO_4 and kept in an ice bath for approximately 10 minutes. The cell suspension is centrifuged and the supernatant decanted and saved. The recombinant proteins present in the supernatant can be separated from the host proteins by standard separation techniques well known to those of skill in the art.

B. Standard Protein Separation Techniques For Purifying Proteins

1. Solubility Fractionation

Often as an initial step, and if the protein mixture is complex, an initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. The preferred salt is ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower

ammonium sulfate concentrations. A typical protocol is to add saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This will precipitate the most hydrophobic of proteins. The precipitate is discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.

2. Size Differential Filtration

Based on a calculated molecular weight, this knowledge can be used to isolate the target protein of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration is then ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed as described below.

3. Column Chromatography

The target protein or protein of interest can also be separated from other proteins on the basis of their size, net surface charge, hydrophobicity and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art.

It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (*e.g.*, Pharmacia Biotech).

Detection and Genomic Analysis of Aging-Associated Proteins.

The polynucleotides and polypeptides of the present invention can be employed as research reagents and materials for discovery of treatments and diagnostics to human disease.

As should be apparent to those of skill, the invention is the identification of aging-associated genes and the discovery that multiple nucleic acids are associated with senescence, cell proliferation, arrested cell growth and/or cell youthfulness. Accordingly, the present invention also includes methods for detecting the presence, alteration or absence of the such associated nucleic acid (*e.g.*, DNA or RNA) in a physiological specimen in order to determine the age of cells *in vitro*, or *ex vivo* and their level of activity, *i.e.*, proliferation state or not, the genotype and risk of senescence or aging associated with mutations created in non-senescent sequences. Although any tissue having cells bearing the genome of an individual, or RNA associated with senescence, can be used, the most convenient specimen will be blood samples or biopsies of suspect tissue. It is also possible and preferred in some circumstances to conduct assays on cells that are isolated under microscopic visualization. A particularly useful method is the microdissection technique described in PCT Published Application No. WO 95/23960. The cells isolated by microscopic visualization can be used in any of the assays described herein including both genomic and immunologic based assays.

This invention provides for methods of genotyping family members in which relatives are diagnosed with premature aging, general aging and skin aging. Conventional methods of genotyping are provided herein.

The invention provides methods for detecting whether a cell is in a senescent state and/or is undergoing senescence. The methods typically comprise contacting RNA from the cell with a probe which comprises a polynucleotide sequence associated with senescence; and determining whether the amount of the probe which hybridizes to the RNA is increased or decreased relative to the amount of the probe which hybridizes to RNA from a non-senescent cell. The assays are useful for detecting senescence associated with, for example, aging-related diseases, such as Werner Syndrome and Progeria. One can also detect whether a cell is arrested at the G₀ stage of the cell cycle using the methods of the invention.

The probes are capable of binding to a target nucleic acid (*e.g.*, a nucleic acid associated with cell senescence). By assaying for the presence or absence of the probe, one can detect the presence or absence of the target nucleic acid in a sample. Preferably, non-

hybridizing probe and target nucleic acids are removed (e.g., by washing) prior to detecting the presence of the probe.

A variety of methods of specific DNA and RNA measurement using nucleic acid hybridization techniques are known to those of skill in the art. See, Sambrook, *supra*.

For example, one method for evaluating the presence or absence of the DNA in a sample involves a Southern transfer. Briefly, the digested genomic DNA is run on agarose slab gels in buffer and transferred to membranes. Hybridization is carried out using the probes discussed above. Visualization of the hybridized portions allows the qualitative determination of the presence, alteration or absence of a senescent gene.

Similarly, a Northern transfer may be used for the detection of senescent-associated mRNA in samples of RNA from cells expressing the senescent proteins. In brief, the mRNA is isolated from a given cell sample using an acid guanidinium-phenol-chloroform extraction method. The mRNA is then electrophoresed to separate the mRNA species and the mRNA is transferred from the gel to a nitrocellulose membrane. As with the Southern blots, labeled probes are used to identify the presence or absence of the subject protein transcript. Alternatively, the amount of, for example, a senescence-associated mRNA can be analyzed in the absence of electrophoretic separation.

The selection of a nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in "Nucleic Acid Hybridization, A Practical Approach," Ed. Hames, B.D. and Higgins, S.J., IRL Press, 1985; Gall and Pardue (1969), *Proc. Natl. Acad. Sci., U.S.A.*, 63:378-383; and John, Burnsteil and Jones (1969) *Nature*, 223:582-587.

For example, sandwich assays are commercially useful hybridization assays for detecting or isolating nucleic acids. Such assays utilize a "capture" nucleic acid covalently immobilized to a solid support and labeled "signal" nucleic acid in solution. The clinical sample will provide the target nucleic acid. The "capture" nucleic acid and "signal" nucleic acid probe hybridize with the target nucleic acid to form a "sandwich" hybridization complex. To be effective, the signal nucleic acid cannot hybridize with the capture nucleic acid.

Detection of a hybridization complex may require the binding of a signal generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and anti-ligand interactions as between a ligand-conjugated probe and an anti-ligand conjugated with a signal. The binding of the signal generation complex is also readily amenable to accelerations by exposure to ultrasonic energy.

The label may also allow indirect detection of the hybridization complex. For example, where the label is a hapten or antigen, the sample can be detected by using antibodies. In these systems, a signal is generated by attaching fluorescent or enzyme molecules to the antibodies or in some cases, by attachment to a radioactive label (*see, e.g.,* Tijssen, P., "Practice and Theory of Enzyme Immunoassays," *Laboratory Techniques in Biochemistry and Molecular Biology*, Burdon, R.H., van Knippenberg, P.H., Eds., Elsevier (1985), pp. 9-20).

The probes are typically labeled directly, as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. Thus, the detectable labels used in the assays of the present invention can be primary labels (where the label comprises an element that is detected directly or that produces a directly detectable element) or secondary labels (where the detected label binds to a primary label, *e.g.,* as is common in immunological labeling). Typically, labeled signal nucleic acids are used to detect hybridization. Complementary nucleic acids or signal nucleic acids may be labeled by any one of several methods typically used to detect the presence of hybridized polynucleotides. The most common method of detection is the use of autoradiography with ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P -labeled probes or the like.

Other labels include ligands which bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand. An introduction to labels, labeling procedures and detection of labels is found in Polak and Van Noorden (1997) *Introduction to Immunocytochemistry*, 2nd ed., Springer Verlag, New York, and in Haugland (1996) *Handbook of Fluorescent Probes and Research Chemicals*, a combined handbook and catalogue Published by Molecular Probes, Inc., Eugene, OR. Primary and secondary labels can include undetected elements as well as detected elements. Useful primary and secondary labels in the present

invention can include spectral labels such as fluorescent dyes (*e.g.*, fluorescein and derivatives such as fluorescein isothiocyanate (FITC) and Oregon Green™, rhodamine and derivatives (*e.g.*, Texas red, tetra-rhodamine isothiocyanate (TRITC), *etc.*), digoxigenin, biotin, phycoerythrin, AMCA, CyDyes™, and the like), radiolabels (*e.g.*, ³H, ¹²⁵I, ³⁵S, ¹⁴C, ³²P, ³³P, *etc.*), enzymes (*e.g.*, horse radish peroxidase, alkaline phosphatase *etc.*), spectral colorimetric labels such as colloidal gold or colored glass or plastic (*e.g.*, polystyrene, polypropylene, latex, *etc.*) beads. The label may be coupled directly or indirectly to a component of the detection assay (*e.g.*, the probe) according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

Preferred labels include those that use: 1) chemiluminescence (using horseradish peroxidase and/or alkaline phosphatase with substrates that produce photons as breakdown products as described above) with kits being available, *e.g.*, from Molecular Probes, Amersham, Boehringer-Mannheim, and Life Technologies/ Gibco BRL; 2) color production (using both horseradish peroxidase and/or alkaline phosphatase with substrates that produce a colored precipitate [kits available from Life Technologies/Gibco BRL, and Boehringer-Mannheim]); 3) hemifluorescence using, *e.g.*, alkaline phosphatase and the substrate AttoPhos [Amersham] or other substrates that produce fluorescent products, 4) fluorescence (*e.g.*, using Cy-5 [Amersham]), fluorescein, and other fluorescent tags; and 5) radioactivity. Other methods for labeling and detection will be readily apparent to one skilled in the art.

Preferred enzymes that can be conjugated to detection reagents of the invention include, *e.g.*, β -galactosidase, luciferase, horse radish peroxidase, and alkaline phosphatase. The chemiluminescent substrate for luciferase is luciferin. One embodiment of a chemiluminescent substrate for β -galactosidase is 4-methylumbelliferyl- β -D-galactoside. Embodiments of alkaline phosphatase substrates include p-nitrophenyl phosphate (pNPP), which is detected with a spectrophotometer; 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) and fast red/naphthol AS-TR phosphate, which are detected visually; and 4-methoxy-4-(3-phosphonophenyl) spiro[1,2-dioxetane-3,2'-adamantane], which is detected with a luminometer. Embodiments of horse radish peroxidase substrates include 2,2'-azino-bis(3-ethylbenzthiazoline-6 sulfonic acid) (ABTS),

5-aminosalicylic acid (5AS), o-dianisidine, and o-phenylenediamine (OPD), which are detected with a spectrophotometer; and 3,3',5,5'-tetramethylbenzidine (TMB), 3,3'-diaminobenzidine (DAB), 3-amino-9-ethylcarbazole (AEC), and 4-chloro-1-naphthol (4C1N), which are detected visually. Other suitable substrates are known to those skilled in the art. The enzyme-substrate reaction and product detection are performed according to standard procedures known to those skilled in the art and kits for performing enzyme immunoassays are available as described above.

In general, a detector which monitors a particular probe or probe combination is used to detect the detection reagent label. Typical detectors include spectrophotometers, phototubes and photodiodes, microscopes, scintillation counters, cameras, film and the like, as well as combinations thereof. Examples of suitable detectors are widely available from a variety of commercial sources known to persons of skill. Commonly, an optical image of a substrate comprising bound labeling moieties is digitized for subsequent computer analysis.

Most typically, the amount of, for example, a senescence-associated RNA is measured by quantitating the amount of label fixed to the solid support by binding of the detection reagent. Typically, presence of a modulator during incubation will increase or decrease the amount of label fixed to the solid support relative to a control incubation which does not comprise the modulator, or as compared to a baseline established for a particular reaction type. Means of detecting and quantitating labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is optically detectable, typical detectors include microscopes, cameras, phototubes and photodiodes and many other detection systems which are widely available.

In preferred embodiments, the target nucleic acid or the probe is immobilized on a solid support. Solid supports suitable for use in the assays of the invention are known to those of skill in the art. As used herein, a solid support is a matrix of material in a substantially fixed arrangement. Exemplar solid supports include glasses, plastics, polymers, metals, metalloids, ceramics, organics, *etc.* Solid supports can be flat or planar, or can have substantially different conformations. For example, the substrate can exist as particles, beads, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, films, plates, dipsticks, slides, *etc.* Magnetic beads or particles, such as magnetic latex beads and iron oxide particles, are examples of solid substrates that can be used in the methods of the

invention. Magnetic particles are described in, for example, US Patent No. 4,672,040, and are commercially available from, for example, PerSeptive Biosystems, Inc. (Framingham MA), Ciba Corning (Medfield MA), Bangs Laboratories (Carmel IN), and BioQuest, Inc. (Atkinson NH). The substrate is chosen to maximize signal to noise ratios, primarily to minimize background binding, for ease of washing and cost.

A variety of automated solid-phase assay techniques are also appropriate. For instance, very large scale immobilized polymer arrays (VLSIPS™), available from Affymetrix, Inc. in Santa Clara, CA can be used to detect changes in expression levels of a plurality of senescence-associated nucleic acids simultaneously. See, Tijssen, *supra*, Fodor *et al.* (1991) *Science*, 251: 767- 777; Sheldon *et al.* (1993) *Clinical Chemistry* 39(4): 718-719, and Kozal *et al.* (1996) *Nature Medicine* 2(7): 753-759. Thus, in one embodiment, the invention provides methods of detecting expression levels of senescence-associated nucleic acids, in which nucleic acids (*e.g.*, RNA from a cell culture), are hybridized to an array of nucleic acids that are known to be associated with cell senescence. For example, in the assay described, *supra*, oligonucleotides which hybridize to a plurality of senescence-associated nucleic acids are optionally synthesized on a DNA chip (such chips are available from Affymetrix) and the RNA from a biological sample, such as a cell culture, is hybridized to the chip for simultaneous analysis of multiple senescence-related nucleic acids. The senescence-associated nucleic acids that are present in the sample which is assayed are detected at specific positions on the chip.

Detection can be accomplished, for example, by using a labeled detection moiety that binds specifically to duplex nucleic acids (*e.g.*, an antibody that is specific for RNA-DNA duplexes). One preferred example uses an antibody that recognizes DNA-RNA heteroduplexes in which the antibody is linked to an enzyme (typically by recombinant or covalent chemical bonding). The antibody is detected when the enzyme reacts with its substrate, producing a detectable product. Coutlee *et al.* (1989) *Analytical Biochemistry* 181:153-162; Bogulavski *et al.* (1986) *J. Immunol. Methods* 89:123-130; Prooijen-Knegt (1982) *Exp. Cell Res.* 141:397-407; Rudkin (1976) *Nature* 265:472-473, Stollar (1970) *PNAS* 65:993-1000; Ballard (1982) *Mol. Immunol.* 19:793-799; Pisetsky and Caster (1982) *Mol. Immunol.* 19:645-650; Viscidi *et al.* (1988) *J. Clin. Microbiol.* 41:199-209, and Kiney *et al.* (1989) *J. Clin. Microbiol.* 27:6-12 describe antibodies to RNA duplexes, including

homo and heteroduplexes. Kits comprising antibodies specific for DNA:RNA hybrids are available, e.g., from Digene Diagnostics, Inc. (Beltsville, MD).

In addition to available antibodies, one of skill can easily make antibodies specific for nucleic acid duplexes using existing techniques, or modify those antibodies which are commercially or publicly available. In addition to the art referenced above, general methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art. See, e.g., Paul (ed) (1993) *Fundamental Immunology, Third Edition* Raven Press, Ltd., New York Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Stites et al. (eds.) *Basic and Clinical Immunology* (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975) *Nature* 256: 495-497. Other suitable techniques for antibody preparation include selection of libraries of recombinant antibodies in phage or similar vectors. See, Huse et al. (1989) *Science* 246: 1275-1281; and Ward et al. (1989) *Nature* 341: 544-546. Specific monoclonal and polyclonal antibodies and antisera will usually bind with a K_D of at least about 0.1 μ M, preferably at least about 0.01 μ M or better, and most typically and preferably, 0.001 μ M or better.

The nucleic acids used in this invention can be either positive or negative probes. Positive probes bind to their targets and the presence of duplex formation is evidence of the presence of the target. Negative probes fail to bind to the suspect target and the absence of duplex formation is evidence of the presence of the target. For example, the use of a wild type specific nucleic acid probe or PCR primers may act as a negative probe in an assay sample where only the nucleotide sequence of interest is present.

The sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system which multiplies the target nucleic acid being detected. Examples of such systems include the polymerase chain reaction (PCR) system and the ligase chain reaction (LCR) system. Other methods recently described in the art are the nucleic acid sequence based amplification (NASBA⁹, Cangene, Mississauga, Ontario) and Q Beta Replicase systems. These systems can be used to directly identify mutants where the PCR or LCR primers are designed to be extended or ligated only when a select sequence is present. Alternatively, the select sequences can be generally amplified using, for example,

nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation.

A preferred embodiment is the use of allelic specific amplifications. In the case of PCR, the amplification primers are designed to bind to a portion of, for example, the senescent protein gene, but the terminal base at the 3' end is used to discriminate between the mutant and wild-type forms of the senescent protein gene. If the terminal base matches the point mutation or the wild-type, polymerase dependent three prime extension can proceed and an amplification product is detected. This method for detecting point mutations or polymorphisms is described in detail by Sommer, S.S., *et al.*, in *Mayo Clin. Proc.* 64:1361-1372,(1989), incorporated herein by reference. By using appropriate controls, one can develop a kit having both positive and negative amplification products. The products can be detected using specific probes or by simply detecting their presence or absence. A variation of the PCR method uses LCR where the point of discrimination, i.e, either the point mutation or the wild-type bases fall between the LCR oligonucleotides. The ligation of the oligonucleotides becomes the means for discriminating between the mutant and wild-type forms of the senescent protein gene.

An alternative means for determining the level of expression of the nucleic acids of the present invention is *in situ* hybridization. *In situ* hybridization assays are well known and are generally described in Angerer, *et al.*, *Methods Enzymol.*, 152:649-660 (1987). In an *in situ* hybridization assay cells, preferentially bovine lymphocytes are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled. The probes are preferably labeled with radioisotopes or fluorescent reporters.

Immunological Detection of Target Protein

In addition to the detection of the target protein genes expression using nucleic acid hybridization technology, one can also use immunoassays to detect target protein. Immunoassays can be used to qualitatively or quantitatively analyze the proteins of interest. A general overview of the applicable technology can be found in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Pubs., N.Y. (1988), incorporated herein by reference.

A. Antibodies to Target Proteins

Methods of producing polyclonal and monoclonal antibodies that react specifically with a protein of interest are known to those of skill in the art. *See, e.g.,* Coligan (1991), CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley/Greene, NY; and Harlow and Lane; Stites *et al.* (eds.) BASIC AND CLINICAL IMMUNOLOGY (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Goding (1986), MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975), *Nature*, 256:495-497. Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors. *See*, Huse *et al.* (1989), *Science*, 246:1275-1281; and Ward *et al.* (1989), *Nature*, 341:544-546. For example, in order to produce antisera for use in an immunoassay, the proteins of interest or an antigenic fragment thereof, is isolated as described herein. For example, recombinant protein is produced in a transformed cell line. An inbred strain of mice or rabbits is immunized with the protein using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen.

Polyclonal sera are collected and titrated against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross reactivity against non-senescent proteins or even other homologous proteins from other organisms, using a competitive binding immunoassay. Specific monoclonal and polyclonal antibodies and antisera will usually bind with a K_D of at least about 0.1 mM, more usually at least about 1 μ M, preferably at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better.

A number of proteins of the invention comprising immunogens may be used to produce antibodies specifically or selectively reactive with the proteins of interest. Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies. Naturally occurring protein may also be used either in pure or impure form. Synthetic peptides made using the protein sequences described herein may also be used as an immunogen for the production of antibodies to the protein. Recombinant protein can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally

described above. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

5 Methods of production of polyclonal antibodies are known to those of skill in the art. In brief, an immunogen, preferably a purified protein, is mixed with an adjuvant and animals are immunized. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to senescent protein. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired (*see*, Harlow and Lane, *supra*).

10 Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (*See*, Kohler and Milstein, *Eur. J. Immunol.* 6:511-519 (1976), incorporated herein by reference). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse, *et al.* (1989) *Science* 246:1275-1281.

20 Once target protein specific antibodies are available, the protein can be measured by a variety of immunoassay methods with qualitative and quantitative results available to the clinician. For a review of immunological and immunoassay procedures in general (*see*, *Basic and Clinical Immunology* 7th Edition (D. Stites and A. Terr ed.) 1991). Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay*, E.T. Maggio, ed., CRC Press, Boca Raton, Florida (1980); "Practice and Theory of Enzyme Immunoassays," Tijssen; and, Harlow and Lane, each of which is incorporated herein by reference.

30 Immunoassays to measure target proteins in a human sample may use a polyclonal antiserum which was raised to the protein partially encoded by a sequence

described herein or a fragment thereof. This antiserum is selected to have low crossreactivity against non-senescent proteins and any such crossreactivity is removed by immunoabsorption prior to use in the immunoassay.

In order to produce antisera for use in an immunoassay, senescent protein or a fragment thereof, for example, is isolated as described herein. For example, recombinant protein is produced in a transformed cell line. An inbred strain of mice, such as Balb/c, is immunized with the protein or a peptide using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen. Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross reactivity against non-senescent proteins, using a competitive binding immunoassay such as the one described in Harlow and Lane, *supra*, at pages 570-573 and below.

B. Immunological Binding Assays

In a preferred embodiment, a protein of interest is detected and/or quantified using any of a number of well recognized immunological binding assays (see, e.g., U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also *Methods in Cell Biology Volume 37: Antibodies in Cell Biology*, Asai, ed. Academic Press, Inc. New York (1993); *Basic and Clinical Immunology* 7th Edition, Stites & Terr, eds. (1991). Immunological binding assays (or immunoassays) typically utilize a "capture agent" to specifically bind to and often immobilize the analyte (in this case the senescent protein or antigenic subsequence thereof). The capture agent is a moiety that specifically binds to the analyte. In a preferred embodiment, the capture agent is an antibody that specifically binds, for example, senescent protein. The antibody (e.g., anti-senescent protein) may be produced by any of a number of means well known to those of skill in the art and as described above.

Immunoassays also often utilize a labeling agent to specifically bind to and label the binding complex formed by the capture agent and the analyte. The labeling agent may itself be one of the moieties comprising the antibody/analyte complex. Thus, the

labeling agent may be a labeled senescent protein polypeptide or a labeled anti-senescent protein antibody. Alternatively, the labeling agent may be a third moiety, such as another antibody, that specifically binds to the antibody/protein complex.

In a preferred embodiment, the labeling agent is a second antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second antibody can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.

Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G, can also be used as the label agent. These proteins are normal constituents of the cell walls of streptococcal bacteria. They exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, generally, Kronval, *et al.* (1973) *J. Immunol.*, 111: 1401-1406, and Akerstrom, *et al.* (1985) *J. Immunol.*, 135: 2589-2542).

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, analyte, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

1. Non-Competitive Assay Formats

Immunoassays for detecting proteins of interest from tissue samples may be either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of captured analyte (in this case the protein) is directly measured. In one preferred "sandwich" assay, for example, the capture agent (*e.g.*, anti-senescent protein antibodies) can be bound directly to a solid substrate where they are immobilized. These immobilized antibodies then capture senescent protein present in the test sample. Senescent protein is thus immobilized is then bound by a labeling agent, such as a second senescent protein antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second can be modified with a detectable moiety,

such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.

2. Competitive Assay Formats

In competitive assays, the amount of target protein (analyte) present in the sample is measured indirectly by measuring the amount of an added (exogenous) analyte (*i.e.*, the target protein) displaced (or competed away) from a capture agent (anti-target protein antibody) by the analyte present in the sample. In one competitive assay, a known amount of, in this case, the target protein is added to the sample and the sample is then contacted with a capture agent, in this case an antibody that specifically binds to the target protein. The amount of target protein bound to the antibody is inversely proportional to the concentration of target protein present in the sample. In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. The amount of the target protein bound to the antibody may be determined either by measuring the amount of target protein present in a target protein/antibody complex or, alternatively, by measuring the amount of remaining uncomplexed protein. The amount of target protein may be detected by providing a labeled target protein molecule.

A hapten inhibition assay is another preferred competitive assay. In this assay, a known analyte, in this case the target protein, is immobilized on a solid substrate. A known amount of anti-target protein antibody is added to the sample, and the sample is then contacted with the immobilized target. In this case, the amount of anti-target protein antibody bound to the immobilized target protein is inversely proportional to the amount of target protein present in the sample. Again, the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

Immunoassays in the competitive binding format can be used for crossreactivity determinations. For example, the protein encoded by the sequences described herein can be immobilized to a solid support. Proteins are added to the assay which compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to the

protein encoded by any of the sequences described herein. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the considered proteins, *e.g.*, distantly related homologues.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps the protein of this invention, to the immunogen protein. In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than 10 times the amount of the protein partially encoded by a sequence herein that is required, then the second protein is said to specifically bind to an antibody generated to an immunogen consisting of the target protein.

3. Other Assay Formats

In a particularly preferred embodiment, Western blot (immunoblot) analysis is used to detect and quantify the presence of target protein in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter) and incubating the sample with the antibodies that specifically bind the target protein. For example, the anti-target protein antibodies specifically bind to the target protein on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (*e.g.*, labeled sheep anti-mouse antibodies) that specifically bind to the anti-target protein antibodies.

Other assay formats include liposome immunoassays (LIA), which use liposomes designed to bind specific molecules (*e.g.*, antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (*see*, Monroe *et al.* (1986) *Amer. Clin. Prod. Rev.* 5:34-41).

4. Reduction of Non-Specific Binding

One of skill in the art will appreciate that it is often desirable to use non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of using such non-specific binding are well known to those of skill in the art. Typically, this involves coating the substrate with a proteinaceous composition. In particular, protein compositions, such as bovine serum albumin (BSA), nonfat powdered milk and gelatin, are widely used with powdered milk being most preferred.

5. Labels

The particular label or detectable group used in the assay is not a critical aspect of the invention, so long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (*e.g.*, Dynabeads™), fluorescent dyes (*e.g.*, fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (*e.g.*, ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P), enzymes (*e.g.*, horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (*e.g.*, polystyrene, polypropylene, latex, *etc.*) beads.

The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (*e.g.*, biotin) is covalently bound to the molecule. The ligand then binds to an anti-ligand (*e.g.*, streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. A number of ligands and anti-ligands can be used.

Thyroxine, and cortisol can be used in conjunction with the labeled, naturally occurring antigens. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

The molecules can also be conjugated directly to signal generating compounds, *e.g.*, by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidotases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, *etc.* Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol. For a review of various labeling or signal producing systems which may be used, see, U.S. Patent No. 4,391,904).

Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, by means of photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally simple colorimetric labels may be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

Screening for Modulators of Senescence

The invention also provides methods of identifying compounds that modulate senescence of a cell. For example, the methods can identify compounds that increase or decrease the expression level of genes associated with senescence and related conditions.

Compounds that are identified as modulators of senescence using the methods of the invention find use both *in vitro* and *in vivo*. For example, one can treat cell cultures with the modulators in experiments designed to determine the mechanisms by which senescence is regulated. Compounds that decrease or delay senescence are useful for extending the useful life of cell cultures that are used for production of biological products such as recombinant proteins. *In vivo* uses of compounds that delay cell senescence include, for example, delaying the aging process and treating conditions associated with premature aging. Conversely, compounds that accelerate or increase cell senescence are useful as anticancer agents, as cancer is often associated with a loss of a cell's ability to undergo normal senescence.

The methods typically involve culturing a cell in the presence of a potential modulator to form a first cell culture. RNA from the first cell culture is contacted with a probe which comprises a polynucleotide sequence associated with senescence. The amount of the probe which hybridizes to the RNA from the first cell culture is determined. Typically, one determines whether the amount of probe which hybridizes to the RNA is increased or decrease relative to the amount of the probe which hybridizes to RNA from a second cell culture grown in the absence of the modulator.

Essentially any chemical compound can be used as a potential modulator in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (for example, DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (*e.g.*, in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.

In one preferred embodiment, high throughput screening methods involve providing a combinatorial library containing a large number of potential therapeutic compounds (potential modulator compounds). Such "combinatorial chemical libraries" are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The

compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (*i.e.*, the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (*see, e.g.*, U.S. Patent 5,010,175, Furka, *Int. J. Pept. Prot. Res.* 37:487-493 (1991) and Houghton *et al.*, *Nature* 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (PCT Publication No. WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication No. WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci. USA* 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114:6568 (1992)), nonpeptidyl peptidomimetics with β -D-glucose scaffolding (Hirschmann *et al.*, *J. Amer. Chem. Soc.* 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen *et al.*, *J. Amer. Chem. Soc.* 116:2661 (1994)), oligocarbamates (Cho *et al.*, *Science* 261:1303 (1993)), and/or peptidyl phosphonates (Campbell *et al.*, *J. Org. Chem.* 59:658 (1994)), nucleic acid libraries (*see*, Ausubel, Berger and Sambrook, *all supra*), peptide nucleic acid libraries (*see, e.g.*, U.S. Patent 5,539,083), antibody libraries (*see, e.g.*, Vaughn *et al.*, *Nature Biotechnology*, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (*see, e.g.*, Liang *et al.*, *Science*, 274:1520-1522 (1996) and U.S. Patent 5,593,853), small organic molecule libraries (*see, e.g.*, benzodiazepines, Baum C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent 5,569,588; thiazolidinones and metathiazanones, U.S. Patent 5,549,974; pyrrolidines, U.S. Patents 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent 5,506,337; benzodiazepines, 5,288,514, and the like).

Devices for the preparation of combinatorial libraries are commercially available (*see, e.g.*, 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). In addition, numerous combinatorial libraries are themselves commercially available (*see, e.g.*, ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, *etc.*).

As noted, the invention provides *in vitro* assays for identifying, in a high throughput format, compounds that can modulate cell senescence. Control reactions that measure the senescence level of the cell in a reaction that does not include a potential modulator are optional, as the assays are highly uniform. Such optional control reactions are appropriate and increase the reliability of the assay. Accordingly, in a preferred embodiment, the methods of the invention include such a control reaction. For each of the assay formats described, "no modulator" control reactions which do not include a modulator provide a background level of binding activity.

In some assays it will be desirable to have positive controls to ensure that the components of the assays are working properly. At least two types of positive controls are appropriate. First, a known activator of cell senescence can be incubated with one sample of the assay, and the resulting increase in signal resulting from an increased expression level of a gene associated with senescence determined according to the methods herein. Second, a known inhibitor of cell senescence can be added, and the resulting decrease in senescence similarly detected. It will be appreciated that modulators can also be combined with activators or inhibitors to find modulators which inhibit the increase or decrease that is otherwise caused by the presence of the known modulator of cell senescence.

In the high throughput assays of the invention, it is possible to screen up to several thousand different modulators in a single day. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100- about 1500 different compounds. It is possible to assay many different plates per day; assay screens for

up to about 6,000-20,000, and even up to about 100,000 different compounds is possible using the integrated systems of the invention.

Compositions, Kits and Integrated Systems

The invention provides compositions, kits and integrated systems for practicing the assays described herein. For example, an assay composition having a nucleic acid associated with, for example, senescence of a cell and a labelling reagent is provided by the present invention. In preferred embodiments, a plurality of, for example, senescence-associated nucleic acids are provided in the assay compositions. The invention also provides assay compositions for use in solid phase assays; such compositions can include, for example, one or more senescence-associated nucleic acids immobilized on a solid support, and a labelling reagent. In each case, the assay compositions can also include additional reagents that are desirable for hybridization. Modulators of expression of, for example, senescence-related nucleic acids can also be included in the assay compositions.

The invention also provides kits for carrying out the assays of the invention. The kits typically include a probe which comprises a polynucleotide sequence associated with senescence; and a label for detecting the presence of the probe. Preferably, the kits will include a plurality of polynucleotide sequences associated with senescence. Kits can include any of the compositions noted above, and optionally further include additional components such as instructions to practice a high-throughput method of assaying for an effect on senescence and expression of senescence-related genes, one or more containers or compartments (e.g., to hold the probe, labels, or the like), a control modulator of senescence, a robotic armature for mixing kit components or the like.

The invention also provides integrated systems for high-throughput screening of potential modulators for an effect on cell senescence. The systems typically include a robotic armature which transfers fluid from a source to a destination, a controller which controls the robotic armature, a label detector, a data storage unit which records label detection, and an assay component such as a microtiter dish comprising a well having a reaction mixture or a substrate comprising a fixed nucleic acid or immobilization moiety.

A number of robotic fluid transfer systems are available, or can easily be made from existing components. For example, a Zymate XP (Zymark Corporation; Hopkinton, MA) automated robot using a Microlab 2200 (Hamilton; Reno, NV) pipetting

station can be used to transfer parallel samples to 96 well microtiter plates to set up several parallel simultaneous STAT binding assays.

Optical images viewed (and, optionally, recorded) by a camera or other recording device (*e.g.*, a photodiode and data storage device) are optionally further processed in any of the embodiments herein, *e.g.*, by digitizing the image and storing and analyzing the image on a computer. A variety of commercially available peripheral equipment and software is available for digitizing, storing and analyzing a digitized video or digitized optical image, *e.g.*, using PC (Intel x86 or Pentium chip-compatible DOS®, OS2® WINDOWS®, WINDOWS NT® or WINDOWS95® based computers), MACINTOSH®, or UNIX® based (*e.g.*, SUN® work station) computers.

One conventional system carries light from the specimen field to a cooled charge-coupled device (CCD) camera, in common use in the art. A CCD camera includes an array of picture elements (pixels). The light from the specimen is imaged on the CCD. Particular pixels corresponding to regions of the specimen (*e.g.*, individual hybridization sites on an array of biological polymers) are sampled to obtain light intensity readings for each position. Multiple pixels are processed in parallel to increase speed. The apparatus and methods of the invention are easily used for viewing any sample, *e.g.*, by fluorescent or dark field microscopic techniques.

Gene Therapy Applications

A variety of human diseases can be treated by therapeutic approaches that involve stably introducing a gene into a human cell such that the gene is transcribed and the gene product is produced in the cell. Diseases amenable to treatment by this approach include inherited diseases, including those in which the defect is in a single gene. Gene therapy is also useful for treatment of acquired diseases and other conditions. For discussions on the application of gene therapy towards the treatment of genetic as well as acquired diseases. See, Miller, A.D. (1992) *Nature* 357:455-460, and Mulligan, R.C. (1993) *Science* 260:926-932, both of which are incorporated herein by reference.

A. Vectors for Gene Delivery

For delivery to a cell or organism, the nucleic acids of the invention can be incorporated into a vector. Examples of vectors used for such purposes include expression plasmids capable of directing the expression of the nucleic acids in the target cell. In other

instances, the vector is a viral vector system wherein the nucleic acids are incorporated into a viral genome that is capable of transfecting the target cell. In a preferred embodiment, the nucleic acids can be operably linked to expression and control sequences that can direct expression of the gene in the desired target host cells. Thus, one can achieve expression of the nucleic acid under appropriate conditions in the target cell.

B. Gene Delivery Systems

Viral vector systems useful in the expression of the nucleic acids include, for example, naturally occurring or recombinant viral vector systems. Depending upon the particular application, suitable viral vectors include replication competent, replication deficient, and conditionally replicating viral vectors. For example, viral vectors can be derived from the genome of human or bovine adenoviruses, vaccinia virus, herpes virus, adeno-associated virus, minute virus of mice (MVM), HIV, sindbis virus, and retroviruses (including but not limited to Rous sarcoma virus), and MoMLV. Typically, genes of interest are inserted into such vectors to allow packaging of the gene construct, typically with accompanying viral DNA, followed by infection of a sensitive host cell and expression of the gene of interest.

As used herein, "gene delivery system" refers to any means for the delivery of a nucleic acid of the invention to a target cell. In some embodiments of the invention, nucleic acids are conjugated to a cell receptor ligand for facilitated uptake (e.g., invagination of coated pits and internalization of the endosome) through an appropriate linking moiety, such as a DNA linking moiety (Wu *et al.*, *J. Biol. Chem.* 263:14621-14624 (1988); WO 92/06180). For example, nucleic acids can be linked through a polylysine moiety to asialoglycoprotein receptor of hepatocytes.

Similarly, viral envelopes used for packaging gene constructs that include the nucleic acids of the invention can be modified by the addition of receptor ligands or antibodies specific for a receptor to permit receptor-mediated endocytosis into specific cells (see, e.g., WO 93/20221, WO 93/14188, WO 94/06923). In some embodiments of the invention, the DNA constructs of the invention are linked to viral proteins, such as adenovirus particles, to facilitate endocytosis (Curiel *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 88: 8850-8854 (1991)). In other embodiments, molecular conjugates of the instant invention can include microtubule inhibitors (WO/9406922); synthetic peptides mimicking influenza virus

hemagglutinin (Plank *et al.*, *J. Biol. Chem.* 269:12918-12924 (1994)); and nuclear localization signals such as SV40 T antigen (WO93/19768).

Retroviral vectors are also useful for introducing the nucleic acids of the invention into target cells or organisms. Retroviral vectors are produced by genetically manipulating retroviruses. Retroviruses are called RNA viruses because the viral genome is RNA. Upon infection, this genomic RNA is reverse transcribed into a DNA copy which is integrated into the chromosomal DNA of transduced cells with a high degree of stability and efficiency. The integrated DNA copy is referred to as a provirus and is inherited by daughter cells as is any other gene. The wild type retroviral genome and the proviral DNA have three genes: the *gag*, the *pol* and the *env* genes, which are flanked by two long terminal repeat (LTR) sequences. The *gag* gene encodes the internal structural (nucleocapsid) proteins; the *pol* gene encodes the RNA directed DNA polymerase (reverse transcriptase); and the *env* gene encodes viral envelope glycoproteins. The 5' and 3' LTRs serve to promote transcription and polyadenylation of virion RNAs. Adjacent to the 5' LTR are sequences necessary for reverse transcription of the genome (the tRNA primer binding site) and for efficient encapsulation of viral RNA into particles (the Psi site). See, Mulligan, R.C., In: *Experimental Manipulation of Gene Expression*, M. Inouye (ed), 155-173 (1983); Mann, R., *et al.*, *Cell*, 33:153-159 (1983); Cone, R.D. and R.C. Mulligan, *Proceedings of the National Academy of Sciences, U.S.A.*, 81:6349-6353 (1984).

The design of retroviral vectors is well known to those of ordinary skill in the art. See, *e.g.*, Singer, M. and Berg, P., *supra*. In brief, if the sequences necessary for encapsidation (or packaging of retroviral RNA into infectious virions) are missing from the viral genome, the result is a *cis* acting defect which prevents encapsidation of genomic RNA. However, the resulting mutant is still capable of directing the synthesis of all virion proteins. Retroviral genomes from which these sequences have been deleted, as well as cell lines containing the mutant genome stably integrated into the chromosome are well known in the art and are used to construct retroviral vectors. Preparation of retroviral vectors and their uses are described in many publications including European Patent Application EPA 0 178 220, U.S. Patent 4,405,712, Gilboa, *Biotechniques* 4:504-512 (1986), Mann, *et al.*, *Cell* 33:153-159 (1983), Cone and Mulligan, *Proc. Natl. Acad. Sci. USA* 81:6349-6353 (1984), Eglitis, M.A., *et al.* (1988) *Biotechniques* 6:608-614, Miller, A.D. *et al.* (1989) *Biotechniques* 7:981-990, Miller, A.D. (1992) *Nature*, *supra*, Mulligan, R.C. (1993), *supra*, and Gould, B. *et*

al., and International Publication No. WO 92/07943 entitled "Retroviral Vectors Useful in Gene Therapy". The teachings of these patents and publications are incorporated herein by reference.

The retroviral vector particles are prepared by recombinantly inserting the desired nucleotide sequence into a retrovirus vector and packaging the vector with retroviral capsid proteins by use of a packaging cell line. The resultant retroviral vector particle is incapable of replication in the host cell and is capable of integrating into the host cell genome as a proviral sequence containing the desired nucleotide sequence. As a result, the patient is capable of producing senescent protein and thus restore the cells to a normal, non-cancerous phenotype.

Packaging cell lines that are used to prepare the retroviral vector particles are typically recombinant mammalian tissue culture cell lines that produce the necessary viral structural proteins required for packaging, but which are incapable of producing infectious virions. The defective retroviral vectors that are used, on the other hand, lack these structural genes but encode the remaining proteins necessary for packaging. To prepare a packaging cell line, one can construct an infectious clone of a desired retrovirus in which the packaging site has been deleted. Cells comprising this construct will express all structural viral proteins, but the introduced DNA will be incapable of being packaged. Alternatively, packaging cell lines can be produced by transforming a cell line with one or more expression plasmids encoding the appropriate core and envelope proteins. In these cells, the *gag*, *pol*, and *env* genes can be derived from the same or different retroviruses.

A number of packaging cell lines suitable for the present invention are also available in the prior art. Examples of these cell lines include Crip, GPE86, PA317 and PG13. See Miller *et al.*, *J. Virol.* 65:2220-2224 (1991), which is incorporated herein by reference. Examples of other packaging cell lines are described in Cone, R. and Mulligan, R.C., *Proceedings of the National Academy of Sciences, USA*, 81:6349-6353 (1984) and in Danos, O. and R.C. Mulligan, *Proceedings of the National Academy of Sciences, USA*, 85: 6460-6464 (1988), Eglitis, M.A., *et al.* (1988), *supra*, and Miller, A.D., (1990), *supra*, also all incorporated herein by reference.

Packaging cell lines capable of producing retroviral vector particles with chimeric envelope proteins may be used. Alternatively, amphotropic or xenotropic envelope

proteins, such as those produced by PA317 and GPX packaging cell lines may be used to package the retroviral vectors.

In some embodiments of the invention, an antisense nucleic acid is administered which hybridizes to an gene associated with aging, senescence, G_0 , or the like, or to transcript thereof. The antisense nucleic acid can be provided as an antisense oligonucleotide (see, e.g., Murayama *et al.*, *Antisense Nucleic Acid Drug Dev.* 7:109-114 (1997)). Genes encoding an antisense nucleic acid can also be provided; such genes can be introduced into cells by methods known to those of skill in the art. For example, one can introduce a gene that encodes an antisense nucleic acid in a viral vector, such as, for example, in hepatitis B virus (see, e.g., Ji *et al.*, *J. Viral Hepat.* 4:167-173 (1997)); in adeno-associated virus (see, e.g., Xiao *et al.*, *Brain Res.* 756:76-83 (1997)); or in other systems including, but not limited, to an HVJ (Sendai virus)-liposome gene delivery system (see, e.g., Kaneda *et al.*, *Ann. N.Y. Acad. Sci.* 811:299-308 (1997)); a "peptide vector" (see, e.g., Vidal *et al.*, *CR Acad. Sci III* 32:279-287 (1997)); as a gene in an episomal or plasmid vector (see, e.g., Cooper *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 94:6450-6455 (1997), Yew *et al.* *Hum Gene Ther.* 8:575-584 (1997)); as a gene in a peptide-DNA aggregate (see, e.g., Niidome *et al.*, *J. Biol. Chem.* 272:15307-15312 (1997)); as "naked DNA" (see, e.g., U.S. 5,580,859 and U.S. 5,589,466); in lipidic vector systems (see, e.g., Lee *et al.*, *Crit Rev Ther Drug Carrier Syst.* 14:173-206 (1997)); polymer coated liposomes (Marin *et al.*, United States Patent No. 5,213,804, issued May 25, 1993; Woodle *et al.*, United States Patent No. 5,013,556, issued May 7, 1991); cationic liposomes (Epand *et al.*, United States Patent No. 5,283,185, issued February 1, 1994; Jessee, J.A., United States Patent No. 5,578,475, issued November 26, 1996; Rose *et al.*, United States Patent No. 5,279,833, issued January 18, 1994; Gebeyehu *et al.*, United States Patent No. 5,334,761, issued August 2, 1994); gas filled microspheres (Unger *et al.*, United States Patent No. 5,542,935, issued August 6, 1996), ligand-targeted encapsulated macromolecules (Low *et al.*, United States Patent No. 5,108,921, issued April 28, 1992; Curiel *et al.*, United States Patent No. 5,521,291, issued May 28, 1996; Groman *et al.*, United States Patent No. 5,554,386, issued September 10, 1996; Wu *et al.*, United States Patent No. 5,166,320, issued November 24, 1992).

C. Pharmaceutical Formulations

When used for pharmaceutical purposes, the vectors used for gene therapy are formulated in a suitable buffer, which can be any pharmaceutically acceptable buffer, such as phosphate buffered saline or sodium phosphate/sodium sulfate, Tris buffer, glycine buffer, sterile water, and other buffers known to the ordinarily skilled artisan such as those described by Good *et al.* (1966) *Biochemistry* 5:467.

The compositions can additionally include a stabilizer, enhancer or other pharmaceutically acceptable carriers or vehicles. A pharmaceutically acceptable carrier can contain a physiologically acceptable compound that acts, for example, to stabilize the nucleic acids of the invention and any associated vector. A physiologically acceptable compound can include, for example, carbohydrates, such as glucose, sucrose or dextran, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives, which are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid. Examples of carriers, stabilizers or adjuvants can be found in Martin, *Remington's Pharm.Sci.*, 15th Ed. (Mack Publ. Co., Easton, PA 1975), which is incorporated herein by reference.

D. Administration of Formulations

The formulations of the invention can be delivered to any tissue or organ using any delivery method known to the ordinarily skilled artisan for example. In some embodiments of the invention, the nucleic acids of the invention are formulated in mucosal, topical, and/or buccal formulations, particularly mucoadhesive gel and topical gel formulations. Exemplary permeation enhancing compositions, polymer matrices, and mucoadhesive gel preparations for transdermal delivery are disclosed in U.S. 5,346,701. In some embodiments of the invention, a therapeutic agent is formulated in ophthalmic formulations for administration to the eye.

E. Methods of Treatment

The gene therapy formulations of the invention are typically administered to a cell. The cell can be provided as part of a tissue, such as an epithelial membrane, or as an isolated cell, such as in tissue culture. The cell can be provided *in vivo*, *ex vivo*, or *in vitro*.

The formulations can be introduced into the tissue of interest *in vivo* or *ex vivo* by a variety of methods. In some embodiments of the invention, the nucleic acids of the invention are introduced to cells by such methods as microinjection, calcium phosphate precipitation, liposome fusion, or biolistics. In further embodiments, the nucleic acids are taken up directly by the tissue of interest.

In some embodiments of the invention, the nucleic acids of the invention are administered *ex vivo* to cells or tissues explanted from a patient, then returned to the patient. Examples of *ex vivo* administration of therapeutic gene constructs include Arteaga *et al.*, *Cancer Research* 56(5):1098-1103 (1996); Nolita *et al.*, *Proc Natl. Acad. Sci. USA* 93(6):2414-9 (1996); Koc *et al.*, *Seminars in Oncology* 23 (1):46-65 (1996); Raper *et al.*, *Annals of Surgery* 223(2):116-26 (1996); Dalesandro *et al.*, *J. Thorac. Cardi. Surg.*, 11(2):416-22 (1996); and Makarov *et al.*, *Proc. Natl. Acad. Sci. USA* 93(1):402-6 (1996).

It is noted that many of the sequences described herein are publicly available in GenBank, which is the NIH genetic sequence database, an annotated collection of all publicly available DNA sequences (*Nucleic Acids Research* 1998 Jan 1;26(1):1-7).

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

G0

GenBank	Clone	Description	SEQ. ID. No.
AA055664	510467	Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	3

LifeSpan	Clone	Description	SEQ. ID. NO.
A0519A27	TRB3Q	Unidentified	1

002075 1444

YOUNG

GenBank	Clone	Description	SEQ. ID. NO.
AA113192	526993	Mucin 5, subtype B, tracheobronchial	4
N99254	309498	ESTs	5
R72302	155943	VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1 PRECURSOR	6
H82718	249107	ESTs	7
AA155854	590209	Matrix protein gla	8
AA102258	511014	EST	9
A032124	MBDP23309	Unidentified	10
H20019	172326	ESTs	11
AA079755	526285	ESTs, Highly similar to ACTIN INTERACTING PROTEIN 1 [Saccharomyces cerevisiae]	12
H10307	46836	Human eIF-2-associated p67 homolog mRNA, complete cds	13
N93806	308273	ESTs	14
W72226	345150	Choline kinase	15
R80779	146868	Human protein kinase (MLK-3) mRNA, complete	16
H20027	172356	EST	17
AA159979	592748	H.sapiens mRNA for serine/threonine protein kinase EMK	18
T94118	119490	EST	19
R83664	187601	EST	20
W90617	417988	ESTs	21
N29836	259818	Pregnancy-specific beta-1 glycoprotein 13	22
N70849	299611	Complement component C1r	23
N99150	310019	H.sapiens mRNA for myosin light chain kinase	24
AA131566	503692	Long chain fatty acid acyl-coA ligase	25
W74375	346533	ESTs	26
AA082829	548498	Casein kinase 2, beta polypeptide	27
M25753	531805	EST similar to G2/mitotic-specific cyclin B1	28
W02712	327105	ESTs, Weakly similar to PROBABLE E5 PROTEIN [Human papillomavirus type 58]	29
N53767	248032	Topoisomerase (DNA) II alpha (170kD)	30
R00817	123564	ESTs, Highly similar to CYTOCHROME C OXIDASE POLYPEPTIDE IV PRECURSOR	31

CYCLIN A

GenBank	Clone	Description	SEQ. ID. NO.
L76937	239597	Werner syndrome gene, complete cds	32
N99256	309499	ESTs	33
AA074996	544516	ESTs	34
N22524	255191	EST	35
H40136	191718	Human 11-cis retinol dehydrogenase mRNA, complete cds	36
R91160	195111	EST	37

PROGERIA

GenBank	Clone	Description	SEQ. ID. NO.
L14812	249856	Retinoblastoma-like 1 (p107)	38
N38735	273876	ESTs	39
H18687	172036	ESTs	40
AA147091	588579	ESTs	41

LifeSpan	Clone	Description	SEQ. ID. NO.
A031327	MBDP23307	Unidentified	2

WERNER'S

GenBank	Clone	Description	SEQ ID. NO.
R71595	142890	ESTs	42
L20046	290120	DNA excision repair protein ERCC5	43
AA165687	592713	EST	44
AA053712	380676	Human cyclin G1 interacting protein (1500GX1) mRNA, complete cds	45
K02581	308571	Thymidine kinase, cytosolic	46
R17721	31097	LIM domain kinase 1	47
AA188105	626544	ESTs	48
W92930	356925	ESTs	49

OLD

GenBank	Clone	Description	SEQ. ID. NO.
H52061	197512	ESTs	50
R16982	129773	EST	51
N25698	267947	WEE1-LIKE PROTEIN KINASE	52
AA128418	565088	ESTs	53
R48587	153614	ESTs	54
N53466	245348	Human 68 kDa type I phosphatidylinositol-4-phosphate 5-kinase alpha mRNA, clone	55
AA148924	503206	DNA-binding protein (SMBP2)	56
H15909	159460	EST, Highly similar to IG KAPPA CHAIN C REGION [Homo sapiens]	57
N29720	258375	ESTs, Highly similar to ANNEXIN III [Homo	58
N64725	293309	ESTs	59
T89591	116279	ESTs	60
N20172	264297	Human Bcl2, p53 binding protein Bbp/53BP2 (BBP/53BP2) mRNA, complete cds	61
H11295	48091	EST	62
R80176	146676	ESTs	63
W49498	325052	ESTs	64
AA147595	590277	CAMP-dependent protein kinase regulatory subunit type 1	65
AA164210	595244	Human cyclin C (CCNC) gene	66
W81700	347397	GLUCOSE TRANSPORTER TYPE 1, ERYTHROCYTE/BRAIN	67
AA083325	546891	General transcription factor IIIA	68
R19138	33211	Human activated p21cdc42Hs kinase (ack) mRNA, complete cds	69
T74308	22568	Homo sapiens ERK3 protein kinase mRNA, complete cds	70
W46981	325065	ESTs	71
AA173173	595670	ESTs	72
N24947	267386	Human 53K isoform of Type II phosphatidylinositol-4-phosphate 5-kinase (PIPK)	73
N93750	308340	RecQ protein-like (DNA helicase Q1-like	74
T62492	79631	ESTs	75

GenBank	Clone	Description	SEQ. ID. NO.
H15530	49281	PEPTIDYL-PROPYL CIS-TRANS ISOMERASE, MITOCHONDRIAL PRECURSOR	76
T71173	84298	Human mRNA for calcium activated neutral protease large subunit (muCANP, calpain, EC	77
R74194	143356	Urokinase-type plasminogen activator	78
H29811	52982	Human focal adhesion kinase (FAK) mRNA, complete cds	79
H84226	219655	ESTs	80
R52055	154220	ESTs	81
N67658	290824	ESTs	82
H27730	162789	ESTs	83
AA167448	595845	ESTs	84
J03250	130119	DNA topoisomerase I	85
H11455	47559	RAS-RELATED PROTEIN RAB-5A	86
N95410	308632	ESTs	87
AA075000	544524	ESTs	88
R74462	143407	ESTs, Highly similar to CAMP-DEPENDENT PROTEIN KINASE INHIBITOR TESTIS ISOFORMS 1 AND 2 ([Mus musculus]	89
H82128	220290	ESTs	90
T65114	21552	Homo sapiens (clone hELK-L) ELK receptor tyrosine kinase ligand (EFL-3) mRNA, complete	91
N50902	281041	ESTs	92
W51835	325674	ESTs	93
AA143795	588530	EST	94
N70879	299711	ESTs	95
W93387	415112	GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE PROTEIN GADD45	96
A042401	KEDP2H41	Unidentified	97
H05114	43883	Eph-related receptor tyrosine kinase ligand 5	98
N91486	306100	ESTs	99
N22982	267450	ESTs	100
R36624	137349	EST	101
H58242	204505	Prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia)	102
T65562	21822	H.sapiens CD24 gene, complete CDS	103

GenBank	Clone	Description	SEQ. ID. NO.
R24291	33870	ESTs	104
R50829	37544	EST	105
N67700	291186	ESTs	106
H05980	43914	ESTs	107
R26536	132395	EST	108
N23153	267592	ESTs	109
AA075075	544808	ESTs	110
R15126	29630	ESTs	111
W46534	323841	ESTs	112
R81839	147839	TKK tyrosine kinase	113
N45541	279363	Adenosine kinase	114
H06301	44415	ESTs	115
AA173084	610146	Human EB1 mRNA, complete cds	116
R27711	134495	ESTs	117
R98882	200884	Human DNA-dependent protein kinase catalytic subunit (DNA-PKcs) mRNA, complete cds	118
N25539	267657	ESTs, Highly similar to NECDIN [Mus musculus]	119
X67325	238520	Interferon-alpha induced 11.5kD protein	120
R69368	142144	ESTs	121
H69287	212239	H.sapiens mRNA for disintegrin-metalloprotease (partial)	122
N63846	293106	Human splicesomal protein (SAP 61) mRNA, complete cds	123

00202750 0444400

OLD + YOUNG

GenBank	Clone	Description	SEQ. ID. NO.
R16982	129773	EST	124
N20172	264297	Human Bcl2, p53 binding protein Bbp/53BP2 (BBP/53BP2) mRNA, complete cds	125
AA167625	632001	Myristoylated alanine-rich C-kinase substrate	126
W49498	325052	ESTs	127
N70690	294248	ESTs	128
AA173173	595670	ESTs	129
T62492	79631	ESTs	130
R52055	154220	ESTs	131
AA075000	544524	ESTs	132
N70879	299711	ESTs	133

OLD + WERNER'S

GenBank	Clone	Description	SEQ. ID. No.
R05264	125068	Human Bruton's tyrosine kinase (BTK), alpha-D-galactosidase A (GLA), L44-like ribosomal protein (L44L) and FTP3 (FTP3) genes, complete cds	134
AA081019	549226	Human protein kinase C-L (PRKCL) mRNA, complete cds	135
N70690	294248	ESTs	136
R44617	33342	ESTs	137
T64839	22042	ESTs	138

OLD + PROGERIA

GenBank	Clone	Description	SEQ. ID. No.
R21132	36410	ESTs	139
AA167625	632001	Myristoylated alanine-rich C-kinase substrate	140

CloneID	SeqID	GeneName	Disease/Change	SEQ. ID. NO.
80671	T57824	Unidentified	Progeria, UP	141
156176	R72819	Latent transforming growth factor-beta binding protein (LTBP-2) (human, 450 nt, 95%)	Progeria, UP	142
130202	U09820	Unidentified	Progeria, UP	143
43133	R60064	Nucleotide binding protein (human, 432 nt, 99%)	Progeria, UP	144
46040	H09005	Protease inhibitor 12 (PI12, neuroserpin) (human, 463 nt, 95%)	Progeria, UP	145
159376	H15003	Unidentified	Progeria, UP	146
159376	H15003	Unidentified	Progeria, UP	147
347396	W81692	Serine protease with IGF-binding motif (human, 593 nt, 98%)	Progeria, UP	148
40844	R55786	A-kinase anchor protein (AKAP100) (human, 494 nt, 93%)	Progeria, UP	149
257679	U11791	Unidentified	Progeria, UP	150
171671	H18310	Evi-5 (mouse, 228 nt, 93%)	Progeria, UP	151
40081	R52529	Unidentified	Progeria, UP	152
347396	W81692	Serine protease with IGF-binding motif (human, 593 nt, 98%)	Werner's, UP	153
40844	R55786	A-kinase anchor protein (AKAP100) (human, 494 nt, 93%)	Werner's, UP	154
257679	U11791	Unidentified	Werner's, UP	155
171671	H18310	Evi-5 (mouse, 228 nt, 93%)	Werner's, UP	156
345228	W72351	Maspin (human, 592 nt, 97%)	Werner's, UP	157
171671	H18310	Evi-5 (mouse, 228 nt, 93%)	Aging fibroblast, UP	158
40081	R52529	Unidentified	Aging fibroblast, UP	159
143407	R74462	Unidentified	Aging fibroblast, UP	160
595845	AA167448	Unidentified	Aging fibroblast, UP	161
143407	R74462	Unidentified	Aging fibroblast, UP	162
366305	AA025672	Unidentified	Aging fibroblast, UP	163
323534	W45706	Aldehyde reductase (human, 569 nt, 94%)	Aging fibroblast, UP	164
595845	AA167448	Unidentified	Aging skin, UP	165
37234	R35283	B lymphocyte serine/threonine protein kinase (human, 470 nt, 92%)	Aging skin, UP	166
37234	R35283	B lymphocyte serine/threonine protein kinase (human, 470 nt, 92%)	Aging skin, UP	167
39819	M18112	Unidentified	Werner's, DOWN	168
240171	H89477	Cyclin D3 (human, 414 nt, 96%)	Werner's, DOWN	169
244390	N52833	Unidentified	Werner's, DOWN	170
39819	M18112	Unidentified	Progeria, DOWN	171

CloneID	SeqID	GeneName	Disease/Change	SEQ. ID. NO.
240171	H89477	Cyclin D3 (human, 414 nt, 96%)	Progeria, DOWN	172
244390	N52833	Unidentified	Progeria, DOWN	173
323534	W45706	Aldehyde reductase (human, 569 nt, 94%)	Progeria, DOWN	174
179163	H50114	NMDA receptor (human, 444 nt, 96%)	Werner's, DOWN	175
240171	H89477	Cyclin D3 (human, 414 nt, 96%)	Aging fibroblast, DOWN	176
244390	N52833	Unidentified	Aging fibroblast, DOWN	177
626544	AA188105	Myosin X (bovine, 634 nt, 81%)	Aging fibroblast, DOWN	178
626544	AA188105	Myosin X (bovine, 634 nt, 81%)	Aging skin, DOWN	179

WHAT IS CLAIMED IS:

- 1 1. An isolated nucleic acid comprising a polynucleotide sequence
2 associated with the senescence of a cell, said polynucleotide sequence encoding a protein
3 that specifically binds to antibodies raised against a protein encoded by SEQ ID NO:1.
- 1 2. The isolated nucleic acid of claim 1 wherein the sequence has at least
2 85% sequence identity with SEQ ID NO:1.
- 1 3. The isolated nucleic acid of claim 1 wherein the sequence has at least
2 95% sequence identity with SEQ ID NO:1.
- 1 4. An isolated protein which is encoded by the nucleic acid of claim 1.
- 1 5. An antibody which selectively binds to the protein of claim 4.
- 1 6. An isolated nucleic acid comprising a polynucleotide sequence
2 associated with the senescence of a cell, said polynucleotide sequence being at least about
3 80% identical to a nucleic acid sequence as set forth in SEQ. ID. NO.:1 over a region at least
4 about 32 nucleotides in length when compared using the BLASTIN algorithm with a
5 Wordlength (W) of 11, M=5, Cutoff=100 and N=4.
- 1 7. An isolated nucleic acid comprising a polynucleotide sequence
2 associated with the senescence of a cell, wherein said polynucleotide sequence hybridizes to
3 a nucleic acid having a sequence as set forth in SEQ. ID. NO:1 under stringent conditions.
- 1 8. An isolated nucleic acid comprising a polynucleotide sequence
2 associated with G₀-arrested cells, said polynucleotide sequence encoding a protein that
3 specifically binds to antibodies raised against a protein encoded by SEQ ID NO:2.
- 1 9. The isolated nucleic acid of claim 8 wherein the sequence has at least
2 85% sequence identity with SEQ ID NO:2.

1 10. The isolated nucleic acid of claim 8 wherein the sequence has at least
2 95% sequence identity with SEQ ID NO:2.

1 11. An isolated protein which is encoded by the nucleic acid sequence in
2 claim 8.

1 12. An antibody which selectively binds to the protein of claim 11.

1 13. An isolated nucleic acid comprising a polynucleotide sequence
2 associated with the senescence of a cell, said polynucleotide sequence being at least about
3 75% identical to a nucleic acid sequence as set forth in SEQ. ID. NO:2 over a region at least
4 about 40 nucleotides in length when compared using the BLASTIN algorithm with a
5 Wordlength (W) of 11, M=5, Cutoff=100 and N=4.

1 14. An isolated nucleic acid comprising a polynucleotide sequence
2 associated with the senescence of a cell, wherein said polynucleotide sequence hybridizes to
3 a nucleic acid having a sequence as set forth in SEQ. ID. NO:2 under stringent conditions.

1 15. A method for detecting the presence of a senescent protein in a human
2 tissue said method comprising:

- 3 (i) isolating a biological sample from a human being tested for
4 senescent protein;
5 (ii) contacting said biological sample with a senescent protein specific
6 reagent; and,
7 (iii) detecting the level of said senescent protein specific reagent that
8 selectively associates with the sample.

1 16. The method of claim 15 wherein said senescent protein specific reagent
2 is a member selected from the group consisting of senescent protein specific antibodies,
3 amplification primers and nucleic acid probes which selectively bind to said protein.

1 17. The method of claim 15 wherein the human from which said biological
2 sample is isolated is suspected of being at risk for premature aging.

1 18. A method for identifying a modulator of senescence of a cell, said
2 method comprising:
3 culturing said cell in the presence of said modulator to form a first cell
4 culture;
5 contacting RNA from said first cell culture with a probe which
6 comprises a polynucleotide sequence associated with senescence; and
7 determining whether the amount of said probe which hybridizes to the
8 RNA from said first cell culture is increased or decrease relative to the amount of said probe
9 which hybridizes to RNA from a second cell culture grown in the absence of said modulator.

1 19. The method of claim 18 wherein said probe comprising at least about 10
2 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID.
3 NOS:2, 38-157 and 168-175.

1 20. The method of claim 18 wherein said polynucleotide sequences is
2 substantially identical to SEQ. ID. NOS:2, 38-157 and 168-175.

1 21. The method of claim 18 wherein said senescence is associated with
2 progeria.

1 22. The method of claim 21 wherein said probe comprising at least about 10
2 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID.
3 NOS:2, 38-41, 139-152 and 171-173.

1 23. The method of claim 18 wherein said senescence is associated with
2 Werner syndrome.

24. The method of claim 23 wherein said probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:42-49, 134-138, 153-157 and 168-170.

25. A method for detecting whether a cell is undergoing senescence, said method comprising:
contacting RNA from said cell with a probe which comprises a polynucleotide sequence associated with senescence; and
determining whether the amount of said probe which hybridizes to the RNA is increased or decrease relative to the amount of said probe which hybridizes to RNA from a non-senescent cell.

26. The method of claim 25 wherein said probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-157 and 168-175.

27. The method of claim 25 wherein the senescence is associated with progeria.

28. The method of claim 25 wherein the senescence is associated with Werner syndrome.

29. A kit for detecting whether a cell is undergoing senescence, said kit comprising:
a probe which comprises a polynucleotide sequence associated with senescence; and
a label for detecting the presence of said probe.

30. The kit in accordance with claim 29 wherein said probe comprises at least about 10 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID. NOS:2, 38-157 and 168-175.

1 31. The kit in accordance with claim 29 further comprising a plurality of
2 probes each of which comprises a polynucleotide sequence associated with senescence; and
3 a label for detecting the presence of said plurality of probes.

1 32. The kit in accordance with claim 31 wherein said probes are
2 immobilized on a solid support.

1 33. The kit in accordance with claim 29 wherein said solid support is a chip.

1 34. A method for identifying a modulator of a G_0 -arrested cell, said method
2 comprising:
3 culturing said cell in the presence of said modulator to form a first cell
4 culture;
5 contacting RNA from said first cell culture with a probe which
6 comprises a polynucleotide sequence associated with G_0 -arrested cells; and
7 determining whether the amount of said probe which hybridizes to the
8 RNA from said first cell culture is increased or decrease relative to the amount of said probe
9 which hybridizes to RNA from a second cell culture grown in the absence of said modulator.

1 35. The method of claim 34 wherein said probe comprising at least about 10
2 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID.
3 NO: 1 and SEQ. ID. NO:3.

1 36. The method of claim 35 wherein said polynucleotide sequence is
2 substantially identical to a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NO: 1 and SEQ. ID. NO:3.

1 37. A method for detecting whether a cell is G_0 -arrested, said method
2 comprising:
3 contacting RNA from said cell with a probe which comprises a
4 polynucleotide sequence associated with G_0 -arrested cells, and

5 determining whether the amount of said probe which hybridizes to the
6 RNA is increased or decrease relative to the amount of said probe which hybridizes to RNA
7 from a non-G₀-arrested cell.

1 38. A kit for detecting whether a cell is G₀-arrested, said kit comprising:
2 a probe which comprises a polynucleotide sequence associated with
3 G₀-arrested cells; and
4 a label for detecting the presence of said probe.

1 39. The kit in accordance with claim 38 wherein said probe comprises at
2 least about 10 nucleotides from a polynucleotide sequence selected from the group
3 consisting of SEQ. ID. NO:1 and SEQ. ID. NO:3.

1 40. A method for identifying a modulator of cyclin A, said method
2 comprising:
3 culturing a cell in the presence of said modulator to form a first cell
4 culture;
5 contacting RNA from said first cell culture with a probe which
6 comprises a polynucleotide sequence associated with cyclin A; and
7 determining whether the amount of said probe which hybridizes to the
8 RNA from said first cell culture is increased or decrease relative to the amount of said probe
9 which hybridizes to RNA from a second cell culture grown in the absence of said modulator.

1 41. The method of claim 40 wherein said probe comprises at least about 10
2 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID.
3 NOS:32-37.

1 42. The method of claim 41 wherein said polynucleotide sequence is
2 substantially identical to a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NOS:32-37.

1 43. A method for modulating cell senescence in a patient in need thereof,
2 said method comprising administering to said patient a compound that modulates the
3 senescence of a cell.

1 44. The method of claim 43 wherein said compound increases or decreases
2 the expression level of a nucleic acid associated with senescence.

1 45. The method of claim 44 wherein said nucleic acid comprises at least
2 about 10 nucleotides from a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NOS:2, 38-157 and 168-175.

1 46. The method of claim 44 wherein said nucleic acid sequence is
2 substantially identical to a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NOS:2, 38-157 and 168-175.

1 47. The method of claim 44 wherein said senescence is associated with
2 progeria.

1 48. The method of claim 47 wherein said nucleic acid comprising at least
2 about 10 nucleotides from a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NOS:2, 38-41, 139-152 and 171-173.

1 49. The method of claim 44 wherein said senescence is associated with
2 Werner syndrome.

1 50. The method of claim 49 wherein said nucleic acid comprising at least
2 about 10 nucleotides from a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NOS:42-49, 134-138, 153-157, 168-170.

1 51. The method of claim 44 wherein said compound is an antisense
2 molecule.

1 52. The method of claim 44 wherein said compound is a ribozyme.

1 53. A method for detecting whether a fibroblast cell is aging, said method
2 comprising:
3 contacting RNA from said fibroblast cell with a probe which comprises
4 a polynucleotide sequence associated with senescence; and
5 determining whether the amount of said probe which hybridizes to the
6 RNA is increased or decrease relative to the amount of said probe which hybridizes to RNA
7 from a non-aging fibroblast cell.

1 54. The method of claim 53 wherein said probe comprising at least about 10
2 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID.
3 NOS:158-164 and 176-178.

1 55. A kit for detecting whether a fibroblast cell is aging, said kit
2 comprising:
3 a probe which comprises a polynucleotide sequence associated with
4 senescence; and
5 a label for detecting the presence of said probe.

1 56. The kit in accordance with claim 55 wherein said probe comprises at
2 least about 10 nucleotides from a polynucleotide sequence selected from the group
3 consisting of SEQ. ID. NOS:158-164 and 176-178.

1 57. A method for modulating the aging of a fibroblast cell in a patient in
2 need thereof, said method comprising administering to said patient a compound that
3 modulates the aging of said fibroblast cell.

1 58. The method of claim 57 wherein said compound increases or decreases
2 the expression level of a nucleic acid associated with the aging of fibroblast cells.

1 59. The method of claim 65 wherein said nucleic acid comprises at least
2 about 10 nucleotides from a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NOS:158-164 and 176-178.

1 60. A method for detecting whether a skin cell is aging, said method
2 comprising:
3 contacting RNA from said skin cell with a probe which comprises a
4 polynucleotide sequence associated with senescence; and
5 determining whether the amount of said probe which hybridizes to the
6 RNA is increased or decrease relative to the amount of said probe which hybridizes to RNA
7 from a non-aging skin cell.

1 61. The method of claim 60 wherein said probe comprising at least about 10
2 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID.
3 NOS:165-167 and 179.

1 62. A kit for detecting whether a skin cell is aging, said kit comprising:
2 a probe which comprises a polynucleotide sequence associated with
3 senescence; and
4 a label for detecting the presence of said probe.

1 63. The kit in accordance with claim 62 wherein said probe comprises at
2 least about 10 nucleotides from a polynucleotide sequence selected from the group
3 consisting of SEQ. ID. NOS:165-167 and 179.

1 64. A method for modulating the aging of a skin cell in a patient in need
2 thereof, said method comprising administering to said patient a compound that modulates the
3 aging of said cell.

1 65. The method of claim 64 wherein said compound increases or decreases
2 the expression level of a nucleic acid associated with the aging of skin cells.

1 66. The method of claim 65 wherein said nucleic acid comprises at least
2 about 10 nucleotides from a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NOS:165-167 and 169.

1 67. A method for identifying a modulator of a young cell, said method
2 comprising:
3 culturing said cell in the presence of said modulator to form a first cell
4 culture;
5 contacting RNA from said first cell culture with a probe which
6 comprises a polynucleotide sequence associated with young cells; and
7 determining whether the amount of said probe which hybridizes to the
8 RNA from said first cell culture is increased or decrease relative to the amount of said probe
9 which hybridizes to RNA from a second cell culture grown in the absence of said modulator.

1 68. The method of claim 67 wherein said probe comprising at least about 10
2 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID.
3 NOS:4-31 and 124-133.

1 69. The method of claim 67 wherein said polynucleotide sequences is
2 substantially identical to a polynucleotide sequence selected from the group consisting of
3 SEQ. ID. NOS:4-31 and 124-133.

1 70. A method for detecting whether a cell is young, said method
2 comprising:
3 contacting RNA from said cell with a probe which comprises a
4 polynucleotide sequence associated with young cells; and
5 determining whether the amount of said probe which hybridizes to the
6 RNA is increased or decrease relative to the amount of said probe which hybridizes to RNA
7 from a non-young cell.

1 71. The method of claim 70 wherein said probe comprises at least about 10
2 nucleotides from a polynucleotide sequence selected from the group consisting of SEQ. ID.
3 NOS:4-31 and 124-133.

1 72. A method for detecting in a test sample the presence or absence of a
2 mutation in a nucleotide sequence essentially encoding human senescent protein comprising;
3 a) contacting said test sample suspected of containing a gene encoding a
4 mutant form of the human senescent protein with a first oligonucleotide having a sequence
5 competent to discriminate between the wild type gene and the mutant form; and,
6 b) detecting the formation of a duplex between the gene and the first
7 oligonucleotide sequence.

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **NUCLEIC ACID SEQUENCES AND PROTEINS ASSOCIATED WITH AGING** the specification of which X is attached hereto or _____ was filed on _____ as Application No. _____ and was amended on _____ (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

Thereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date
60/081,887	4/15/98

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Eugenia Garrett-Wackowski, Reg. No. 37,330
Ellen L. Weber, Reg. No. 32,762
Timothy L. Smith, Reg. No. 35,367

Send Correspondence to: Eugenia Garrett-Wackowski TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834	Direct Telephone Calls to: (Name, Reg. No., Telephone No.) Name: Eugenia Garrett-Wackowski Reg. No.: 37,330 Telephone: 415-576-0200
--	--

Full Name of Inventor 1:	Last Name: BURMER	First Name: GLENNA	Middle Name or Initial: C.	
Residence & Citizenship:	City: Seattle	State/Foreign Country: Washington	Country of Citizenship: USA	
Post Office Address:	Post Office Address: 7516 55th Place, NE	City: Seattle	State/Country: Washington	Postal Code: 98115
Full Name of Inventor 2:	Last Name: BROWN	First Name: JOSEPH	Middle Name or Initial: P.	
Residence & Citizenship:	City: Seattle	State/Foreign Country: Washington	Country of Citizenship: United Kingdom	
Post Office Address:	Post Office Address: 411 West Prospect Street	City: Seattle	State/Country: Washington	Postal Code: 98119

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
<hr/>	<hr/>	<hr/>
GLENN C. BURMER	JOSEPH P. BROWN	
Date	Date	Date

SF 212299 v1

SEQUENCE LISTING

SEQ ID NO:1

1 ATGGGCCACT CCTNTCCGGC GCATNGCGCG GATTACATNC CCCAGTTGTA
 51 NCNANGACAC ATAAATCTGT GCTGCTATTC ATCTAACTCT GAACTCCANA
 101 ACACCANACG CTTGTNCATT CACTGTNNTA TGACACTTTC TCTCCGGGGT
 151 GGANGGGGANG GCNCGTGACT GTGTANNNCA ATATGTGGAA TNAAATATTG
 201 TCTATAACNT NTCATCACGT ANNACANNCT CTATTATGCA TACCTANGGG
 251 GANNAACNCC TCCCTTCTAN NNTNATTENG AAGGANNGGG ANAATNNNTC
 301 CTNCCTCNAN NTNANCNATN NCNTTNANNA AANGACACNT GGAGATCACN
 351 GNCCTCTCNC ANAAATNNTT CNTCACTTGT CCCATCGANA NGTNGTTNTC
 401 GCCCTGNCAT CCCNCNCTGT AANATNATCN ATCGCTNATC CCATGCGNCG
 451 CTGCAGTCAC CTNTGGANAC TCCCCCTNG GATCNNCTNA NTATCNTNTN
 501 TCCTTNTGTC TTGCNTCTCA GGCTGCTNT TCNGTTGA

SEQ ID NO:2

1 NCNNTNCCAT GTCGGCCCCA GTCACGNCAT ACTGANCATC TGACCGGGAT
 51 ATAGTGTGGG TCCACACATC AGTCCCGACA CNAATGTGAT GTGGCACATA
 101 AGGATTCTCC GCATANACAC AGCGACAATC TCGTCNGCAT AGTGGTAGGT
 151 ATGATCNACA TGGGCCCGAT CCATCTAACG GCGCACGCGG GACCACTTGT
 201 CCTNATAGGT AATGCCCTGG CTACATGCTA CTTCTTTACT GTNCCCCCAC
 251 CCCANCTACA CCGACNTNTT TNCCGGTCTA NATACACTCA ATATGCTGCC
 301 CCTGCCCTCA TCGAACNGTC TGCACTNATA TACTGCAN